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1. ABBREVIATIONS 
AC1  adenylyl cyclase 1 
AC8  adenyl  yl cyclase 8 
ADP  Adenosine diphosphate 
AKT  A serine/threonine protein kinase 
ATP  Adenosine triphosphate 
cAMP  cyclic adenosine monophosphate 
CNS  central nervous system 
DA  dopamine 
DAT  dopamine transporter 
DNA  2-desoxyribonucleic acid 
DOPAC  3,4-Dihydroxyphenylacetic acid  
Drd1  Family member of dopamine receptor D1 
Drd2  family member of dopamine receptor D2 
D1   Dopamine receptors witch activate adenyl cyclase and production  
of cyclic adenosine monophosphate, also known as DRD1 
D2  Dopamine receptor D2, wich inhibits the production of cyclic 
adenosine monophosphate also known as DRD2 
ER  endoplasmic reticulum 
EPAC2  exchange protein, directly activated by cAMP 2 also known as 
RAPGEF4 
GABA  gamma-aminobutyric acid 
GABAA  gamma aminobutyric acid (GABA) receptor A 
GABRA1  gene that codes GABAA receptor subunit alpha-1 
GABRA2  gene that codes GABAA receptor subunit alpha-2 
GAD1  Glutamate decarboxylase 1 
GAD2  Glutamate decarboxylase 2 
GIP  Gastric inhibitory polypeptide, member of incretins 
GLP1  glucagon-like peptide 1,  member of incretins 
GLUT2  Glucose transporter 2 
GPCR  G protein-coupled receptors 
Gs  heterotrimeric G protein subunit that activates the cAMP-dependent 
pathway by activating adenylate cyclase 
GTP  guanosine monophosphate 
HVA  Homovanillic acid 
L-DOPA  L-3,4-dihydroxyphenylalanine, precursor to the neurotransmitters 
dopamine, norepinephrine (noradrenaline), and epinephrine 
(adrenaline) 
MAO  monoamine oxidase, breaks down free dopamine 
9 
mRNA  messenger ribonucleic acid (RNA) 
NLS  nuclear localization signal or sequence 
NMDA  N-methyl-D-aspartate, an selective agonist that binds to NMDA 
receptors but not to other glutamate receptors 
PI3K  Phosphatidylinositide 3-kinases 
PKA  cAMP-dependent protein kinase A 
PKC  Protein kinase C (PKC) is a family of serine- and threonine-
specific protein kinases that can be activated by calcium 
PKG  cGMP-dependent protein kinase or Protein Kinase G 
UPR  unfolded protein response 
VMAT2  The vesicular monoamine transporter 2 
Wfs1  Wolfram syndrome 1 gene or protein in any species other than 
human 
WFS1  Wolfram syndrome 1 gene or protein in human 
Wfs1bgal/bgal   Wfs1 deficient mouse strain expressing truncated Wfs1 protein 
fused to beeta galactosidase reporter enzyme 
WS  Wolfram syndrome 
3MT  3-Methoxytyramine 
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2. INTRODUCTION 
Wolfram syndrome (WS, Online Mendelian Inheritance in Man [OMIM] 
222300) is a rare autosomal recessive neurodegenerative disorder characterized 
by early-onset diabetes mellitus, progressive optic atrophy, diabetes insipidus, 
and deafness (Domenech et al., 2006). WS was first characterized by Wolfram 
and Wagener in 1938. WFS1/wolframin has been identified as the causative 
gene (Strom et al., 1998; Inoue et al., 1998). There are a number of con-
siderations from the viewpoint of nervous system function making Wfs1 gene 
and protein attractive objects for studies (Luuk, 2009). First, WS is ac-
companied by a variety of neurological and psychiatric symptoms, including  
severe depression, psychosis, impulsivity, and aggressiveness (Barrett et al., 
1995; Swift et al., 1991; Swift et al., 1990). Secondly, carriers of WfS1 gene 
mutations, who are not affected with Wolfram Syndrom, have a 26-fold higher 
likelihood of psychiatric hospitalization mainly due to depression (Swift et al., 
1998). Third, Wfs1 has been implicated in fear and anxiety-related behaviors in 
rodents (Kesner et al., 2009; Koks et al., 2002) and its polymorphisms are 
possibly associated with increased risk for mood disorders (Koido et al., 2005). 
The WfS1 gene locates at 4p16.1 (Strom et al., 1998; Inoue et al., 1998), a 
replicated linkage locus of bipolar disorder (Ewald et al., 1998, 2002; Detera-
Wadleigh et al., 1999). Some studies showed that bipolar disorder with 
psychosis (Als et al., 2004; Cheng et al., 2006) or suicidal behavior (Cheng et 
al., 2006) are linked with this locus. These lines of evidence suggested the 
possible role of WfS1 gene mutations in the pathophysiology of bipolar disorder 
and related phenotypes (Kato et al., 2008).  
Moreover, there are studies demonstrating the mutations of WFS1 gene in 
patients suffering from neuropsychiatric disorders (Ohtsuki et al., 2000; 
Martorell et al., 2003; Torres et al., 2001; Crawford et al., 2002; Evans et al., 
2000). It is important to stress that none of these patients had mutations causing 
WS. Despite the fact that WFS1 gene mutations are probably not frequent 
causes of mental disorders, understanding the mechanism of how WFS1 gene 
mutations lead to mental symptoms in patients with WS will shed light on the 
pathophysiology of neuropsychiatric disorders (Kato et al., 2008). Indeed, the 
neurobiological mechanisms of neuropsychiatric alterations due to WFS1 gene 
deficiency are not clear. However, by taking into account the psychiatric 
symptoms accompanying WS (Barrett et al., 1995; Swift et al., 1991; Swift et 
al., 1990) as well as the localization of Wfs1 gene and protein in the brain 
(Luuk et al., 2008) may suggest that the impaired function of γ-aminobutyric 
acid (GABA)- and dopaminergic systems could be among the reasons for the 
development of mental disorders in these patients. Extensive comorbidity 
among major depressive disorder and anxiety disorders suggests related disease 
etiologies  (Murphy et al., 2004; Gamez et al., 2007). Reduced brain con-
centrations of the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and 
altered function or reduced expression of its principal GABAA receptors are 
increasingly implicated in depressive and anxiety disorders (Luscher et al., 
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2011). On the other hand, it has been shown that the hypoactivity of dopami-
nergic system, particularly in the prefrontal cortex, has been associated with the 
negative symptoms of depression and schizophrenia (apathy, loss of interest, 
anhedonia etc.) (Davis et al., 1991). By contrast, the hyperactivity of the 
dopaminergic system, especially in the ventral and dorsal striatum, has been 
linked to the positive symptoms of schizophrenia such as hallucinations, 
delusions, psychomotor restlessness and uncontrollable behaviour (Davis et al., 
1991). These neuropsychiatric symptoms related to the altered function of 
GABA- and dopaminergic system very much resemble that occurring in relation 
to WFS1 deficieny in humans (Swift et al., 1998).  
The major goal of this doctoral thesis was to generate a model of WS in 
laboratory animals. For this purpose a mutant mouse line was created by 
deleting exon 8 of the Wfs1 gene and by inserting a beta galactosidase 
expression cassette (NLS-LacZ) in its place. The 8th exon was chosen for 
deletion, because our aim was to create a C-terminal „loss of function“ mouse 
model of the Wfs1 protein as the majority of the mutations observed in WS 
patients are located in that exon. This enabled to create a WS-like condition in 
mice to study the pathologies caused by WS. The first part of study was 
dedicated to the behavioural phenotyping of Wfs1 deficient mice. According to 
the performed studies the impaired function of GABA- and dopaminergic 
system was revealed in these mutant mice. The following steps were taken to 
characterize more thoroughly these neurochemical alterations occurring in 
Wfs1-deficient mice. First, the relation between the impaired adaptation in the 
stressful environment and functional activity of GABAA receptors, the major 
targets of anxiolytic drugs, was analyzed in Wfs1 deficient mice. Second, in 
order to reveal the possible deviations in the functioning of dopaminergic 
system in Wfs1-deficient mice the experiments were performed using dopamine 
agonists with the different mechanism of action: amphetamine (undirect 
agonist) and apomorphine (direct agonist) as well as the measurments of 
dopamine and its metabolite levels in the dorsal and ventral striatum. Finally, 
based on the performed experiments the validity of mutant mice as the model 
WS was evaluated.  
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3. REVIEW OF LITERATURE  
3.1.  Wolfram syndrome 
Wolfram syndrome (WS) is a very rare autosomal recessive disease, described 
first in 1938 by Wolfram and Wagener, who studied eight siblings with a juvenile 
diabetes mellitus accompanied by vision impairment (Wolfram and Wagener 
1938). This syndrome is also known as DIDMOAD (diabetes insipidus, diabetes 
mellitus, optic atrophy, deafness). In addition to endocrinological disturbances, 
WS is characterised by optic atrophy, deafness, dementia, urinary tract atony, 
ataxia, mental retardation, peripheral neuropathy, glaucoma, epilepsy, bipolar 
disorder, depression and schizophrenia (Swift et al., 1990; Swift et al., 1991).  
The first symptoms of WS are diabetes and optic atrophy that appear during 
the first two decades. Renal tract abnormalities appear in the third decade and, 
as a rule, in the fourth decade several severe neurological complications will be 
evident (Barrett et al., 1995; Hansen et al., 2005; Cano et al., 2007). However, 
the recent evidence suggests that the neurodegeneration is already evident in 
early childhood (Hershey et al., 2012) and it is fully manifested for a age 15 
(Chaussenot et al., 2011). Moreover, recent study by Hershey et al. (2012) 
demonstrates abnormalities in the brainstem and cerebellum, as well as increase 
in intracranial volume already in young patients. This finding suggests that 
WFS has a pronounced impact on early brain development in addition to later 
neurodegenerative effects, representing a significant new insight into the WFS 
disease process. Generally the average life expectancy of WS patients is 30 
years, the death being caused by neurodegeneration and urinary tract atony.  
WS is caused by mutations in the Wfs1 gene, which in humans is located on 
chromosome 4p16.1 (Inoue et al., 1998). The prevalence of WS in the UK has 
been estimated to be 1 in 770,000 and in North America 1 in 100,000 (Fraser et 
al., 1977; Barrett et al., 1995). The frequency of heterozygous Wfs1 mutation car-
riers is 1 in 345 in the UK and about 1 in 100 in the USA (Swift et al., 1991; 
Barrett et al., 1995). 
Mutations in 4p16 region where the Wfs1 gene is located have also been 
observed in patients with Huntington’s disease, Wolf-Hirschhorn syndrome, 
night blindness and psychiatric diseases like bipolar disorder, depression and 
schizophrenia (Blackwood et al., 1996; Asherson et al., 1998; Ewald et al., 
2002; Koido et al., 2005;  Christoforou et al., 2007). Depressive and psychotic 
symptoms have been found in about 60% of WS patients. It has been estimated 
that even heterozygous mutations in the Wfs1 gene elevate the risk of 
psychiatric hospitalization 26 times (Swift et al., 1998).  
In WS patients over 100 mutations have been identified (71 point mutations, 
37 deletions and 14 insertions )(Figure 1). The majority of them are located in 
the 8th exon that modifies the hydrophilic C-terminal part of the protein. 
Generally the mutations in the Wfs1 gene are patient-specific (there are also 
compound heterozygotes), which makes the timely diagnosis of the disease 
much more difficult as the whole sequence of the gene must be studied (Cryns 
et al., 2003; Cano et al., 2007). 
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3.2.  WFS1 gene and protein 
In humans the Wfs1 gene is located on the short arm of the 4th chromosome 
(4p16.1) and in mice on the long arm of the 5th chromosome (5qB3). There is a 
83% overlap in the nucleotide sequence of the Wfs1 gene and a 87% overlap in 
the amino acid sequence of its protein in humans and mice (Strom et al., 1998). 
The length of the gene is 33.4 kb. The gene consists of eight exons the first of 
which is noncoding, thus the transcription starts from the second exon (Inoue et 
al., 1998). The 8th exon is the largest (2.8 kb), containing about 60% of the 
whole protein-coding sequence of the Wfs1 gene. The majority of the mutations 
(deletions, insertions, nonsense and missense mutations) described in WS 
patients are located in this exon. On rare occasions, mutations have also been 
found in exons 3, 4, 5 and 6. The Wfs1 mRNA consists of 3,640 nucleotides 
and the coding sequence is 2,673 nucleotides long (Cryns et al., 2003). The 
product of the Wfs1 gene, wolframin, consists of 890 amino acids and has a 
molecular weight of approximately 100 kDa. Wolframin is a transmembrane 
protein that is located in the membrane of the endoplasmatic reticulum (ER). Its 
amino-terminal domain is in the cytoplasm and carboxy-terminal domain in the 
ER lumen. Wolframin has nine transmembrane segments (Fig. 1) (Hofmann et 
al., 2003; Inoue et al., 1998; Strom et al., 1998). 
The expression level of Wfs1 is the highest in the brain, heart, lung, liver, 
spleen, skeletal muscles, kidney and neurosecretory tissues, including pan-
creatic insulin-secreting β-cells (Inoue et al., 1998; Strom et al., 1998; Hofmann 
et al., 2003). It has been found that in the mouse brain, the Wfs1 gene expres-
sion level is higher in brain structures related to emotions, learning and me-
mory. Luuk et al. (2008) have showed that a very strong expression of the Wfs1 
gene is detectable in the central extended amygdala and ventral striatum. 
Prominent Wfs1 expression was detected in the hippocampal CA1 region, para-
subiculum, superficial part of the second and third layers of the prefrontal 
cortex and proisocortical areas, hypothalamic magnocellular neurosecretory 
system, and central auditory pathway. Wfs1 expression was also detected in 
numerous brainstem nuclei and in laminae VIII and IX of the spinal cord. Wfs1-
positive nerve fibers were found in the medial forebrain bundle, reticular part of 
the substantia nigra, globus pallidus, posterior caudate putamen, lateral lemnis-
cus, alveus, fimbria, dorsal hippocampal commissure, subiculum, and to a lesser 
extent in the central sublenticular extended amygdala, compact part of substan-
tia nigra, and ventral tegmental area (Luuk et al., 2008). Besides, it has been 
shown that neurons expressing the Wfs1 gene project from the nucleus 
accumbens to the midbrain dopaminergic neurons. Therefore, the Wfs1 protein 
could be one of the most important regulators of the function of mesolimbic 
dopaminergic neurons (Luuk et al., 2008). In conclusion, the expression level of 
Wfs1 is the highest in brain structures that belong to or are closely associated 







Figure 1. Schematic overview of the Wfs1 gene in humans. The hypothetical structure 
of the WFS1 protein that consists of nine transmembrane segments. Mutations cousing 
the single amino acid changes in WFS1 protein. Mutation definition – the first letter 
denotes the wild type amino acid, the number after first letter denotes its position in the 
WFS1 protein sequence. The last letter denotes mutanted form. If there is deletion, the 





3.3.  The functions of the Wfs1 gene  
The Wfs1 protein is localized in the ER, where proteins are folded and mo-
dified, and thus obtain a proper three-dimensional structure necessary for 
normal functioning. ER is also involved in transporting proteins, lipids, Ca2+ 
ions and many other materials needed by the different parts of the cell (Osman 
et al.,2003; McBain and Morgan, 2003; Ishihara et al., 2006).  
On the other hand, WFS1 takes part in the regulation of intracellular Ca2+ 
homeostasis and influences the viability of insulin-secreting β-cells (including 
insulin secretion) both in vitro and in vivo experiments (Osman et al.,2003; McBain 
and Morgan, 2003; Ishihara et al., 2006). In pancreas, Wfs1 plays a role in the 
processing and secretion of insulin in response to glycose stimuli that are presented 
after a meal (Osman et al., 2003; Ishihara et al.,2004). Recent studies have revealed 
that the Wfs1 protein is present in the secretory granules of pancreatic -cells, 
where it could be directly implicated in the release of insulin (Hatanaka et al., 
2011). The transmembrane part of the Wfs1 protein and its C-terminal domain 
interact with the Na+/K+-ATPase 1 subunit, calmodulin and adenylate cyclase 8 
(Osman et al., 2003; Zatyka et al., 2007, Fonseca et al., 2012).  
Recently Fonseca et al. (2012) showed that WFS1 plays a really important 
role in regulation of insulin secretion and UPR response (Fonseca et al., 2012). 
Insulin secretion (in pancreatic -cells) is typically initiated by a rise in extra-
cellular glucose in the pancreatic -cells (GLUT2 mediated glucose intake), 
which is detected by a metabolic signalling pathway. Aerobic glycolysis and 
mitochondrial oxidation produce metabolic signals, such as a rise in the ATP to 
ADP concentration ratio, witch closes K+ATP-channels, depolarizes the plasma 
membrane, and causes calcium influx that stimulates exocytosis (Fonseca et al., 
2012). At the same, the GLP1 and GIP (incretin hormones) bind to their re-
ceptors on on pancreatic β-cells witch causes the activation of Gs proteins. The 
glucose and GLP1 signalling pathways cross on AC8.  AC8 is fully activated 
when both Gαs-GTP and calcium-calmodulin are bound (Fonseca et al., 2012).  
AC8 generates cAMP from ATP which is essential for insulin secretion. The 
subsequent rise in cellular cAMP triggers exocytosis by cAMP-dependent 
protein kinase A (PKA) and EPAC2, resulting in an increase in the number of 
vesicles that are highly sensitive to Ca2+ (Fonseca et al., 2012; Lemaire et al., 
2012 ). WFS1 interacts with calmodulin and AC8 in glucose-dependent manner 
to stimulate cAMP synthesis and calcium activation of enzymatic flux. It is 
possible that the physical interaction between AC8 and calmodulin is regulated 
by WFS1. Furthermore, Fonseca et al. (2012) showed that WS associated muta-
tions inhibited the formation of AC8-calmodulin complex and insulin secretion. 
They demonstrated that glucose stimulation causes the translocation of WFS1 
from the ER to the plasma membrane, where it interacts with AC8. ER stress 
blocks these translocations and interactions (Fonseca et al., 2012; Lemaire et 
al., 2012). Fonseca et al. (2012) proposed that WSF1 is not only a molecular 
„switch“ for insulin release, but it also regulates insulin synthesis. As long as 
ER can manage with protein folding (after glycose stimulated insulin secretion), 
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WFS1 mediated stimulation of AC8 continues and cAMP increases insulin 
mRNA synthesis (Lemaire et al., 2012) 
There is less information about the role of WFS1 in neurotransmission.  It is 
not clear yet whether WFS1 generates the cAMP signal for exocytosis or 
regulates the genes involved in synaptic plasticity.  AC8 and AC1 (calmodulin 
activated adenylate cyclase 1) are expressed in neurons and are implicated in 
synaptic plasticity and long-term memory (Wang and Storm, 2002). Also it has 
been shown that WFS1 binds to calcium-calmodulin in the rat neurons through 
its N-terminal cytoplasmatic domain and this interaction was lost by WS as-
sociated mutations (Yurimoto et al., 2009). However, the role of WFS1 in 
neurons and neurotransmission is far from being clear and it can be more 
complicated than established for the pancreatic -cells. 
 
 
3.4.  Wfs1-deficient mouse as a model for Wolfram 
syndrome and other diseases 
In order to study Wfs1 deficiency in vivo, two Wfs1-deficient mouse models 
have been created so far by different research groups. The first one was created 
by Riggs and colleagues (2005). Their model is a conditional Wfs1 exon 8 
knock-out mouse (in a 129SVJ genetic background) with a pancreatic cells 
specific deletion of exon 8 of the Wfs1 gene. These mice are viable and fertile 
and display no deviances from Mendelian genotypic distribution. Male mice 
were used in the experiments. Riggs and colleagues (2005) found that this 
mouse had a progressive glucose intolerance and insulin-deficiency and by 4 
months of age these mice have developed a type 2 diabetes-like condition. At 6 
months of age, the body weight of homozygous mice is significantly lower than 
in wild-type controls. Also, smaller mass of insulin-producing pancreatic β-cells 
and increased apoptosis and ER stress level of these cells were observed in 
mutant mice, which reflects a type 2 diabetes-like condition (Riggs et al., 2005). 
The second model was published by Ishihara and colleagues in 2004. Their 
mouse model is a so-called „full knock-out” as exon 2 of the Wfs1 gene has been 
deleted in these mice. Preliminary studies revealed that mutant mice responded 
with decreased insulin secretion in the glucose tolerance test and as the result of 
which by the increased blood sugar levels. Progressive loss of pancreatic β-cells, 
caused by apoptosis and ER stress, manifests in these mutants as type 2 diabetes-
like condition only in 129/SVEV x C57BL6 F2 genetic background. In C57 
background, these mice do not develop overt diabetes; thus it can be concluded 
that this background protects mice to certain extent against diabetes caused by 
Wfs1-deficiency. In conclusion, these authors argued that WFS1 protein played 
an important role in insulin exocytosis and the maintenance of β-cell mass. In 
behavioural experiments, these knock-out mice had a significantly shorter escape 
latency in the habituation phase of the passive and active avoidance tests. They 
displayed increased freezing in the training phase of the fear conditioning test and 
longer latency to find the platform in the learning phase of the Morris water maze 
test (Ishihara et al., 2004; Kato et al., 2008). 
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3.5. Potential neurochemical targets of Wfs1-deficiency 
Our preliminary sudies established that Wfs1 deficient mice displayed the aug-
mented anxiety-like responses and significant inhibition in the locomotor acti-
vity tests.  Therefore, the next part of literature overview is dedicated to the 
GABA- and dopaminergic systems as the key neurochemical mechanisms in the 
regulation of emotional behaviour and locomotor activity.   
 
 
3.5.1. GABA-ergic mechanisms 
GABA is widely distributed neurotransmitter in the brain. Its effects are me-
diated both via GABAA and GABAB receptor. GABAA receptor is an ionotropic 
receptor and a ligand-gated ion channel (Ortells and Lunt 1995). This trans-
membrane ion channel opens or closes only when a „messenger” chemical (e.g. 
neurotransmitter) binds to it. GABAB receptor is a metabotropic transmembrane 
receptor linked via G-proteins to potassium channels (Chen et al., 2005). The 
changing potassium concentrations hyperpolarize the cell at the end of an action 
potential. GABA is synthesized from glutamate by means of glutamate 
decarboxylase, which is coded in humans by Gad1 and Gad2 genes. Both are 
expressed mainly in the central nervous system, but Gad2 expression has also 
been found in the pancreas. The deficiency of these two genes has been linked 
with Parkinson’s disease, schizophrenia, bipolar disorders and type 1 diabetes 
(Ludvigsson et al., 2008; Woo et al., 2004; Lewitt et al., 2011). 
GABA itself is not an inhibitory neurotransmitter as it stimulates the 
GABAA receptor (inhibition is caused by receptor activation). GABAA receptor 
activation results in the efflux of chloride ions and thereby the membrane of the 
neuron becomes hyperpolarized. This inhibits neurotransmission as the gene-
ration of action potential is suppressed (Richter et al., 2012). 
GABAA receptor has several ligand-binding sites. GABA itself binds 
between the alpha and beta subunits (which is also the binding site for musci-
mol, gaboxadol and bicuculline). However, the binding sites for benzo-
diazepines are located between the alpha and gamma subunits (for those types 
of GABAA receptors that have these subunits). The majority of GABAA re-
ceptors are sensitive to benzodiazepines and those that are not, are generally 
sensitive to other neurostimulators such as ethanol, barbiturates, anesthetics and 
neurosteroids (Richter et al., 2012).  
Moderate GABAA receptor activation causes an anxiolytic effect in patients 
and powerful inhibition of these receptors induces general anesthesia. Binding 
of benzodiazepines changes the conformation of GABAA receptors, which in its 
own increases the affinity of GABA for GABAA receptors. Due to this change 
the transport of chloride ions intensifies and the hyperpolarization of the memb-
rane of neurons increases. This amplifies the anxiolytic or sedative effect of 
GABA itself. Different benzodiazepines have a different affinity to GABAA 
receptor and they bind to different alpha subunits. For example, benzodia-
zepines that have high affinity to alpha1 or alpha5 subunits have a sedative 
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effect, whereas benzodiazepines that have high affinity to alpha2 or alpha 3 
subunits exert an anxiolytic effect (Richter et al., 2012). 
GABAA receptor subunits have many different isoforms. Nineteen different 
GABAA receptor subunits have been identified in the mammal central nervous 
system (α1–6, β1–3, γ1–3, δ, ɛ, π, θ, ρ1–3) that are coded by different genes 
(Richter et al., 2012).  
Classical benzodiazepine diazepam binds to GABAA receptors that consist 
of the following subunits (the binding site is on the outer layer of the subunits, 
between alpha and gamma subunits): α1βγ2, α2βγ2, α3βγ2 and α5βγ2. It has 
also been shown that when diazepam binds to alpha1 subunit, it has a sedative 
effect and when it binds to alpha2 subunit, it has a stimulating effect. Therefore, 
in studying the effect of diazepam, the genes coding these subunits (Gabra1 and 
Gabra2) are of utmost importance  (Richter et al., 2012; Olsen et al., 2009; 
Wafford et al., 2004).  
Besides the central nervous system, GABA and GABAA receptors are also 
present in the pancreas. Pancreatic β-cells release insulin alongside with GABA, 
which inhibits the release of glucagon from pancreatic α-cells by binding to 
GABAA receptors. Therefore, besides neurotransmission in the central nervous 
system, GABA and GABAA receptors play (similarly to Wfs1 protein) a very im-
portant role in the regulation of blood sugar level and metabolism (Xu et al., 
2006). 
 
3.6. Dopaminergic mechanisms 
3.6.1. Dopamine and its receptors  
in the central nervous system and pancreas 
Dopamine (DA) is a catecholamine, an important neurotransmitter and a neuro-
hormone that is produced already in the early stages of embryonic development 
and plays a major role in the development of the central nervous system. 
Generally, dopamine is produced in neurons (Ohtani et al., 2003). Dopamine is a 
water-soluble signaling molecule that exerts its effects by binding to the receptors 
on the cell surface, thereby influencing the functioning of cells. Dopamine 
activates five different types of dopaminergic receptors (D1–D5). All dopamine 
receptors belong to the family of G protein-coupled receptors (GPCR) and are 
pharmacologically classified into two major groups, based on how they influence 
the activity of adenyl cyclase (dopamine D1 and D2 receptors). Doopamine 
(Drd1) D1 receptors activate adenyl cyclase, whereas dopamine D2 (Drd2) 
receptors inhibit the production of cAMP (Missale et al., 1998). 
In the brain, Drd1 receptors are the most widely expressed. Drd1 mRNA has 
been identified in the dorsal striatum (dorsolateral caudate-putamen), ventral 
striatum (incl. nucleus accumbens and olfactory tubercle), hypothalamus and 
thalamus. Drd2 receptors (D2S, D2L, D3 ja D4) can be found primarily in the 
striatum, nucleus accumbens, hypothalamus, substantia nigra and cortex (Mis-
sale et al., 1998). In addition, it has been shown that Drd2 receptors are also 
expressed in pancreatic β-cells, where they play an important role in insulin 
secretion (Rubi et al., 2005). 
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In the brain dopamine is mainly produced in the dopaminergic neurons 
located in the midbrain’s ventral tegmental area and substantia nigra. The mid-
brain’s dopaminergic neurons are the primary source of dopaminergic terminals 
(Chinta et al., 2005). Dopamine synthesis starts from amino acid tyrosine. Tyro-
sine is assimilated from food or converted from phenylalanine by phenylalanine 
hydroxylase in the liver and by tyrosine hydroxylase in the dopaminergic 
neurons. The influx of tyrosine into neurons is mediated by amino acid trans-
porters (Bressan and Crippa, 2005). Tyrosine is synthesized by tyrosine hydro-
xylase into dihydroxyphenylalanine (L-DOPA, which is a precursor of dopa-
mine and which passes differently from dopamine the blood-brain barrier). L-
DOPA is converted by L-amino acid decarboxylase into dopamine. Dopamine is 
a precursor of noradrenaline and therefore also of adrenaline. Dopamine is de-
graded by monoamine oxidases (MAO) and catechol-O-methyltransferase into 3-
methoxy-tyramine (3MT), 3,4-dihydroxy-phenylacetic acid (DOPAC) and homo-
vanillic acid (HVA) (Cooper et al., 1996). Dopamine reuptake into presynaptic 
neurons is mediated by dopamine transporter (DAT) (Afonso et al., 2010). 
Dopaminergic neurotransmission regulates motor activity (including the 
fluency of movements and speech), pleasure responses (sexual and feeding 
behaviour, different addictions). In the peripheral nervous system dopamine 
controls the functioning of the cardiovascular system, influences the release of 
hormones etc (Feldman et al., 1997). Excessive dopamine levels in the brain 
have been associated with the positive symptoms of schizophrenia and develop-
ment of alcoholism. On the other hand, hypoactivity of the dopamine system 
may contribute to the negative symptoms characteristic to psychiatric disorders 
(lack of motivation, anhedonia, difficulties in adaptation, withdrawal from 
society etc) (Velligan and Alphs, 2008). 
Dopamine is preserved and held in the synaptic vesicles and also in the 
endoplasmatic reticulum of neuronal dendrites (Bressan and Crippa, 2005). 
Vesicular monoamine transporter VMAT2 is a transporter protein, which is 
located primarily in the membrane of the intracellular vesicle of presynaptic 
neurons and participates in transporting monoamines into synaptic vesicles. In 
neurons, VMAT2 accumulates dopamine, serotonin, norepinephrine and hista-
mine. The activity of VMAT2 is necessary for preserving neurotransmitters for 
later release into the synapse, otherwise these molecules would be degraded. 
Thus, in dopaminergic neurons, VMAT2 collects and preserves both freshly 
synthesized neurotransmitter molecules and molecules that have been elimi-
nated from the synapse by reuptake (Takahashi et al., 1997; Eiden et al., 2011). 
The arrival of action potential changes the conformation of the cell 
membrane and that results in the influx of Ca2+ ions. This leads to the fusion of 
the dopamine-containing vesicle with the membrane of a neuron and dopamine 
is released into presynapse. Dopamine release is strongly modulated by GABA 
and glutamate (Bressan and Crippa, 2005). 
It is interesting to note that in addition to neurons, VMAT2 is also expressed 
in the pancreatic insulin-secreting β-cells (being a diagnostic marker for 
diabetes) (Raffo et al., 2008; Siuta et al., 2010) and is present there along with 
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insulin (Saisho et a.l, 2008). Supposedly VMAT2 regulates glucose homeo-
stasis, insulin production, and the transport and preservation of monoamines 
(dopamine and serotonin) in the β-cells (Raffo et al., 2008). 
It has been shown that besides neural transmission, dopamine and Drd2 
receptors play also a role in the regulation of blood sugar level. For example, 
both dopamine agonists and Drd2 agonists (e.g. L-DOPA and quinpirole) 
inhibit glucose-stimulated insulin secretion in vitro (Rubi et al., 2005; Rosati et 
al., 1976; Ericson et al., 1977; Zern et al., 1980). Production of Dopamine 
occurs locally in the β-cells, and it is transported and preserved in insulin 
containing vesicles. Therefore, the high extracellular dopamine concentration 
inhibits the release of insulin. During glucose-stimulated insulin secretion also 
dopamine, serotonin, Drd2 receptors, GABA and Ca2+ ions are released that all 
regulate the further secretion of insulin and blood sugar homeostasis (Raffo et 
al., 2008; Paulmann et al., 2009). 
 
 
3.6.2. Dopaminergic pathways  
in the central nervous system (Fig. 2) 
The are several dopaminergic pathways in the brain, which transmit signals 
from one part of the brain to another by means of neurotransmitter dopamine. 
The nuclei consisting of dopaminergic neurons are labelled A8–A16. Nuclei 
A8–A10 are located in the midbrain, A11–A14 in the diencephalon, A15 in the 
forebrain and A16 in the olfactory bulb (Bjorklund et al., 1984; Swanson et al., 
1982). Approximately 90% of the dopaminergic neurons are located on the 
ventral side of the midbrain (Shankar et al., 2005). Several dopaminergic path-
ways start from these regions. There are eight different dopaminergic systems; 
the four most important ones are following:  
Nigrostriatal pathway – The nigrostriatal pathway transmits dopamine from 
the substantia nigra to the striatum. This pathway is associated with motor 
control and habit formations (Pierce et al., 2006). 
Mesolimbic pathway – The mesolimbic dopaminergic pathway connects the 
midbrain’s ventral tegmental area (VTA) with the structures belonging to the 
forebrain’s limbic system (nucleus accumbens, hippocampus, amygdala and 
prefrontal cortex). Most of the neurons projecting from the VTA are dopamine-
producing and their activation results in a massive release of dopamine into 
nucleus accumbens and prefrontal cortex. This system is related to the moti-
vational aspects of behaviour and is also one of the main targets for addictive 
drugs. Furthermore, deviations in this system are associated with the symptoms 






Figure 2. Distribution of DA neuron cell groups in the rodent brain in a schematical 
sagittal view. The principal projections of the DA cell groups are illustrated by arrows. 
Drawing is modified from Bjorklund and Dunett (2007). 
 
 
Mesocortical pathway – The mesocortical pathway transmits dopamine from 
the VTA to the frontal cortex. This pathway is associated with the negative 
symptoms of schizophrenia (Pierce et al., 2006). 
Tuberoinfundibular pathway – The tuberoinfundibular pathway transmits 
dopamine from the hypothalamus to the pituitary gland. This pathway influen-
ces the secretion of certain hormones, including prolactin. This pathway is 
associated with hyperprolactinaemia (Pierce et al., 2006; Bjorklund et al., 1984; 
Swanson et al., 1982). 
 
 
3.6.3. Relevance of dopamine transporter  
for dopaminergic neurotransmission 
Dopamine transporter (DAT) is a transmembrane glucoprotein that pumps 
dopamine from the synaptic cleft back into the presynaptic cytoplasm (or the 
other way round), where it is packed again into monoamine vesicles (VMAT2 
vesicles) for preservation and later release (Afonso et al., 2010). DAT-mediated 
dopamine reuptake is powered by the ion concentration gradient created by the 
Na-pump in the plasma membrane. The function of DAT in the cell membrane 
is regulated by different secondary signalling molecules, e.g. protein kinase A, 
protein kinase C, protein kinase G, tyrosine kinases, phosphatases, calcium and 
calmodulin-dependent kinases, and arachidonic acid (Gonzalo et al., 2006). 
DAT is expressed primarily in dopaminergic neurons, but its expression has 
been found also in the peripheral tissues, including lymphocytes (Ramamoorthy 
et al., 2011). DAT is the most abundant in those brain regions that are related to 
dopaminergic neurotransmission: nucleus accumbens, nucleus caudatus, sub-
stantia nigra, amygdala and ventral tegmental area (Staley et al., 1994; Torres et 
al., 2003). Impairments in the functioning of DAT have been described in 
several neuropsychiatric diseases like Parkinson’s disease, bipolar disorder, 
schizophrenia, depression and different addictions (Kahling et al., 2006).  
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Dopamine release from the axon terminals of neurons is dependent on neural 
activity, Ca2+ channels and also insulin (Adachi et al., 2005). Insulin has a direct 
effect on the brain’s mesolimbic dopaminergic system and this effect is 
mediated primarily by DAT. Namely, insulin plays a role in the transport of 
DAT from the plasma membrane into cytosol and vice versa (Owens et al., 
2005). For example, in hypoinsulinemic rats the DAT-mediated dopamine 
reuptake from the synapse has decreased (Patterson et al., 1998). In mice with 
streptozotocin-induced diabetes, dopamine reuptake is about 45% lower than in 
the control group (Owens et al., 2005). These results show that lower level of 
insulin is directly associated with impaired dopamine reuptake.  
Psychostimulant amphetamine releases dopamine from the presynapse of 
neurons via DAT and blocks dopamine reuptake (essentially it puts DAT to work 
only one-way). Released dopamine activates Drd2 receptors to the greatest extent in 
the ventral and dorsal striatum. It was shown already in 1970s that in rats with a 
streptozotocin-induced type 1 diabetes amphetamine failed to increase locomotor 
activity, because amphetamine was not able to release dopamine. This effect was 
reversible by injecting insulin into the brain (Marshall, 1978). 
 
 
3.7. State of art and definition of tasks for present study 
According to the existing clinical studies majority of WS patients suffer from 
neuropsychiatric symptoms. On the other hand, heteozygous mutations of 
WFS1 gene significantly increase the risk to be hospitalized due to the neuro-
psychiatric disease (Swift et al., 1998). Moreover, the mutations of WFS1 gene 
have been described in patients suffering from bipolar disorder, major 
depressive disorder and schizophrenia (Kato et al., 2008). Besides that WFS1 
gene belongs to the genes which mutations increase risk for type 2 diabetes. 
Interestingly, this is in line with the findings that the frquency of type 2 diabetes 
is significantly elevated among the patients suffering from bipolar depression 
and schizophrenia (Coclami and Cross 2011). 
Taken together, it is apparent that the genetically modified knock out mouse 
model is a valid model to reflect the disturbances in glucose metabolism present 
in WS patients (Ishihara et al., 2004; Riggs et al., 2005). Since most of the 
mutations in WFS1 gene are located in exon 8 in WS patients suffering from the 
psychiatric symptoms a new Wfs1 exon 8 knock-out mice model would have a 
potential for establishing of connections between metabolic and neuro-
psychiatric disorders. Therefore, the major goal of the present work was to 
generate Wfs1 exon 8 knock-out mice. The initial step was the phenotyping of 
these mice keeping in mind both the neuropsychiatric and metabolic symptoms 
occurring in humans suffering from WS and neuropsychiatric disoders. Since 
the disturbances of emotional behaviour and locomotor activity were domi-
nating in these animals the psychopharmacological approach was taken to 
reveal the alterations of GABA- and dopaminergic systems in animals lacking 
Wfs1 gene.  
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4. AIMS OF THE STUDY 
Based on the literature review an attempt was done to generate the animal 
model of WS and to study the possible alterations in the behaviour and neuro-
chemistry caused by Wfs1 deficiency. The majority of mutations causing WS 
are located in the 8th exon of WFS1 gene. Therefore, the approach following 
the human pathology was used for the invalidation of Wfs1 gene. Namely the 
8th exon of Wfs1 gene was corrupted using the transgenic technology. After 
building up the animal colony the behavioural and psychopharmacological 
characterization of these mouse was started. For that purpose following  specific 
tasks were set:  
1. The initial phenotyping of Wfs1-deficient mouse to describe the mutants in 
adaptation-, learning- and anxiety-related behavioural experiments and to 
measure the levels of stress hormones compared to wild-type controls. 
Simultaneously with the behavioural measures the alteration of glucose 
metabolism was studied in mice lacking Wfs1 gene. 
2. Since the increased anxiety was dominating feature of behavioural pheno-
type in Wfs1 deficient mice an attempt was taken to characterize the para-
meters of GABAergic system.  The expression levels of alpha1 and alpha2 
subunits of GABAA receptors and the Gad1 and Gad2 genes were measured 
in the brain structures associated with the regulation of behavioural 
adaptation, learning and anxiety (temporal lobe, frontal cortex, mesolimbic 
system and hippocampus). This study was performed both in the experi-
mentally naive mice and in animals challenged to the elevated plus-maze 
model of anxiety. 
3. The suppressed locomotor activity was the other behavioural feature of Wfs1 
deficient mice. Therefore, the changes in the activity of dopaminergic 
system, playing a central role in the regulation locomotor activity, were 
characterized in Wfs1 deficient mice. For that purpose the behavioural and 
biochemical effects of dopamine agonists (amphetamine, apomorphine) were 
analyzed. In order to confirm the established alterations in the behavioural 
and biochemical levels, the gene and protein expression experiments, 
involving DAT and Drd2 receptor, were performed in the midbrain, ventral 
and dorsal striatum of wild-type and Wfs1 deficient mice. 
4. Finally, based on the performed behavioural, biochemical and psycho-
pharmacological studies the validity of Wfs deficient mice for modelling of 
metabolic and neuropsychiatric symptoms in WS patients was evaluated. 
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5. MATERIALS AND METHODS 
5.1.  Animals and generation of Wfs1  
gene deficient mice (Study 1, 2, 3) 
The third model of Wfs1 deficient mice was generated at the University of 
Tartu (see the description of other two in the review of literature). In these 
conventional Wfs1 knock-out mice, exon 8 in the Wfs1 has been deleted. This 
is the exon where most of the mutations have been found in WS patients. In 
mutants, exon 8 has been replaced by NLS-LacZ-Neo expression cassette, 
which enables to observe the expression patterns of the Wfs1 gene (Fig. 3). By 
contrast, the N-terminal domain of the protein remained functional. 
Wfs1 targeting construct was created by subcloning a 8.8 kb BamHI fragment 
from 129SvEv/TacfBr mouse genomic PAC clone 391-J24 (RPCI21 library, 
MRC U.K. HGMP Resource Centre, U.K.) including introns 6–7 and exons 7–8 
of Wfs1 gene into pGem11 cloning plasmid (Promega). A 3.7 kb NcoI fragment 
was replaced by an in-frame NLSLacZNeo cassette, deleting more than 90% of 
the 8th exon and 60% of the total coding sequence including 8 of the 9 predicted 
transmembrane domains. A pgk-TK negative selection cassette was cloned 
upstream of 5’ genomic arm. NotI-linearized targeting construct was electro-
porated into W4/129S6 embryonic stem (ES) cells (Taconic) which were selected 
for resistance to Neomycin and Gancyclovir. ES cell colonies were tested for 
homologous recombination by PCR using recombination-specific primer pair 
NeoR1 5’ GACCGCTATCAGGACATAGCG and Wfs1_WTR1 5’ 
AGGACTCAGGTTCTGCCTCA. PCR-product was sequenced to verify the 
integration site. ES cell clone 8A2 was injected into C57BL/6 blastocysts and 
heterozygous F1 mice were established by mating male chimeras with C57BL/6 
female mice. F2 generation homozygous Wfs1-deficient animals were obtained 
by crossing heterozygous F1 mice. Mice were genotyped by multiplex PCR for 
both alleles using primers WfsKO_wtF2 5’ TTGGCTTGTATTTGTCGGCC, 
NeoR1 5’ GACCGCTATCAGGACATAGCG and WfsKO_uniR2 5’ 





Figure 3. The strategy of making Wfs1 knock-out mouse. Exon 8 in the Wfs1 gene was 
replaced with NLS-LacZ-Neo expression cassette (Luuk et al., 2008). 
 
 
Breeding and genotype analysis of mice were performed in the Department of 
Physiology, University of Tartu. Mice were F2 hybrids with 129S6/SvEvTac 
and C57BL/6J mixed genetic background. The mixed background was chosen 
to eliminate gene-gene interaction effects specific to a single inbred back-
ground. Instead, we sought to unravel general behavioural effects of Wfs1-
deficiency apparent in a genetically heterogeneous population. In the beha-
vioural, biochemical and gene/protein expression studies only littermates were 
used and compared. The mice were housed in groups of eight under a 12 hour 
light/dark cycle with lights on at 7:00 a.m. All three genotypes (wild-type, 
heterozygous and homozygous Wfs1-deficient) were housed in their respective 
home cages. The studies were performed between 9:00 a.m. and 7:00 p.m. The 
animals had free access to food and water except during testing. Mutant mice 
were always used in parallel with wild-type mice and the animals were taken 
into groups randomly. The permissions for the present study was given by the 
Estonian National Board of Animal  experiments (no. 39, 7 October 2005; No. 
13 from 16.09.2009) in accordance with the European Communities Directive 
of November 1986 (86/609/EEC) (Luuk et al., 2009). 
 
 
5.2. Drugs (study 1, 2, 3) 
 All injections were performed in a volume of 10 ml/kg. Amphetamine (2.5, 5, 
7.5 mg/kg, amphetamine sulfate, Sigma-Aldrich, St Louis, MO, USA.), an 
indirect agonist of dopamine, a compound increasing the release of neuro-
transmitter from the presynaptic terminals. Amphetamine was diluted in 0.9% 
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NaCl (B. Braun Melsungen AG, Germany) and  given intraperitoneally (i.p.)  30 
min prior to the experiment. Apomorphine (3 mg/kg, apomorphine hydro-
chloride, Sigma-Aldrich, St Louis, MO, USA), an unselective Drd1 and Drd2 
receptor agonist, was also dissolved in physiological saline. Ascorbic acid was 
added to the final concentration of 0.1% to prevent the oxidation of apo-
morphine. Apomorphine was given subcutaneously (s.c.) 15 min before the 
experiment. Diazepam (1 mg/kg, Grindex, Latvia), an anxiolytic GABAA recep-
tor agonist, was diluted in saline. Diazepam was given  i.p. 30 min prior to 
testing. 
 
5.3. Behavioral Studies (Study 1, 2, 3) 
Capturing and analysis of vocalizations 
AT803b omnidirectional condenser microphone (Audio-Technica, Japan) with a 
working frequency response range of 100 Hz to 10 kHz was attached above the 
Plexiglas chamber used for monitoring locomotor activity of single mice. Audio 
recordings (44.1 kHz sampling frequency, 16 bit depth) were captured on 
computer hard disc using US122 audio interface (Tascam, U.S.A.) and adjusted 
for volume using CoolEdit Pro 2.0 (Syntrillium, U.S.A.). Sonogram was gene-
rated with SasLab Light application (Avisoft, Germany) (Luuk et al., 2009). 
 
Rota-rod test 
Motor performance and coordination was assessed by rota-rod. A 1-min training 
session was given to each mouse on the rota-rod (diameter 8 cm, 9 rpm) 5 min 
before the first measurement. Motor performance (time until the first fall) was 
registered during a 2-min session (Luuk et al., 2009). 
 
Stress-induced analgesia 
Stress was induced by electric foot-shocks (0.2, 0.4, 0.6 mA, alternating current) 
during 3 min in the apparatus used for active and passive avoidance testing (TSE 
Systems, Germany). Each group of mice received electric foot-shocks of a single 
intensity only. Withdrawal latencies in the radiant-heat tail flick test (Plantar Test 
7371, TSE Systems) were measured before (baseline) and after stress treatment. 
The post-stress latences were measured immediately after termination of foot-
shocks. Removal of the tail from the heat source terminated the application of 
thermal stimulation. Ceiling tail-flick latencies were 30 s. Restraint tubes (opaque 
plastic cylinders, inner diameter 28 mm, length 90 mm, the closed end of the tube 
had a small hole for breathing) were used for the immobilization of mice during 
the measurement. Mice were habituated with the tubes for 5 days prior to the 
measurements (Luuk et al., 2009). 
 
Locomotor activity 
Locomotor activity of single mice was measured for 30 min in sound-proof 
photoelectric motility boxes (448 mm × 448 mm × 450 mm) connected to a 
computer (TSE, Technical & Scientific Equipment GmbH, Germany). In the 
first study we investigated the effect of illumination on locomotor activity of 
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Wfs1-deficient mice. The experiment was performed both in dimly (20 lx) and 
brightly (450 lx) lit conditions. Half of the animals were first exposed to 
brightly lit motility boxes and the second half to dimly lit motility boxes. On the 
second day the treatments were reversed so that each animal experienced both 
conditions. The results from the two experiments were collapsed. In the second 
study we investigated the effects of amphetamine (2.5–7.5 mg/kg) and 
apomorphine (3 mg/kg) on locomotor activity. Amphetamine and apomorphine 
were injected i.p. at 30 and 15 min, respectively, prior to the measurement of 
locomotor activity in a brightly lit environment (450 lx). The schedule of 
experiments is presented in Table 1. For each individual, the effect of 
amphetamine was compared to the mean effect of saline treatments performed 
in the same individual on days 4 and 20. Similarly, the effect of apomorphine 
was compared to the mean effect of saline treatments performed on days 20 and 
28. The floor of the testing apparatus was cleaned with damp towels and dried 
thoroughly after each mouse. Computer registered the distance travelled, the 
number of rearings and corner entries, and time spent in the central part of 
motility boxes (Luuk et al., 2009). 
 
 
Table 1. Pharmacological treatment schedule in locomotor activity experiment 
Day Treatment 
1–3 Habituation with the motility boxes 
4 Treatment with saline 
8 Treatment with amphetamine (2.5 mg/kg) 
12 Treatment with amphetamine (5 mg/kg) 
16 Treatment with amphetamine (7.5 mg/kg) 
20 Treatment with saline 
24 Treatment with apomorphine (3 mg/kg) 
28 Treatment with saline 
Luuk et al., 2009 
 
 
Elevated plus-maze test 
The test employs a naturalistic conflict in mice between the tendency to explore 
a novel environment and aversive properties of a brightly lit, open area 
(Handley et al., 1984; Lister 1987; Pellow et al., 1985). The plus-maze 
consisted of two opposite open arms (17.5 cm × 5 cm) without sidewalls and 
two enclosed arms of the same size with 14-cm-high sidewalls and an end wall. 
The arms extended from a common central square (5 cm × 5 cm) and were 
perpendicular to each other, making the shape of a plus sign. The entire plus-
maze apparatus was elevated to a height of 30 cm and placed in a dim room 
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(illumination level ~20 lx). In order to encourage open arm exploration, a 
slightly raised edge (0.25 cm) was put around the perimeter of the open arm, 
providing a grip for animals. The open arms were divided into three equal parts 
by lines. The anxiolytic effect of diazepam, a GABAA receptor agonist, on 
exploratory activity was studied in Wfs1-deficient mice and their wild-type 
littermates isolated for 30 min before the experiment. Diazepam was 
administered 30 min before the study. The control group received saline. 
Testing began by placing an animal on the central platform of the maze facing 
an open arm. An arm entry was counted only when all four limbs were within a 
given arm. Standard 5-min test duration was employed (Lister 1987; Pellow et 
al., 1985) and the maze was wiped clean with damp and dry towels between the 
subjects. Test sessions were video-recorded and the videotapes were sub-
sequently blind-scored by a trained observer. The following measures were 
registered by the observer: (1) time spent on open arms; (2) number of closed 
and open arm entries (entries into the most distant part of open arms were 
counted separately); (3) number of line crossings; (4) ratio between open and 
total arm entries; (5) number of head dips; (6) number of attempts to enter the 
central platform located between open and closed arms (Luuk et al., 2009, Raud 
et al., 2009). 
 
Light-dark box exploration test 
Light-dark box exploration test is another unconditioned test of anxiety-like 
behaviour designed for mice (Crawley et al., 1980). Since social isolation is 
known to affect exploratory activity (Abramov et al., 2004), the effect of short-
term isolation on the behaviour of Wfs1-deficient mice was tested explicitly. 
One group of animals was exposed to the exploration test without previous 
isolation (non-isolated animals), the second group was isolated for 15–20 min 
before the experiment. The experiments were carried out in a dim room 
(illumination ~20 lx). Plexiglas box (45 cm × 20 cm × 20 cm) was divided into 
two parts: 2/3 was brightly illuminated (~270 lx) and 1/3 was painted black, 
covered by a lid and separated from the white compartment with a partition 
containing an opening (13 cm × 5 cm). A mouse was placed in the centre of the 
light compartment facing away from the opening between the two compart-
ments, and, during 5 min, latency to move into the dark compartment, time 
spent in the light compartment and number of transitions between the two com-
partments were recorded (Luuk et al., 2009). 
 
Fear conditioning test 
This is a form of classical conditioning which investigates the establishment of 
a simple association between a conditioned stimulus (10 kHz tone, CS) with an 
unconditioned aversive stimulus (0.5 mA electric foot-shock with a duration of 
2 s, US). The study was performed according to the method described by Paylor 
et al. (Paylor et al., 1998) with some modifications. Experiments were carried 
out with a computer-controlled fear conditioning system (TSE). Context and 
tone-dependent experiments took place in a lit room. During the training period 
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and on the day of the experiment, mice were kept in their home cages. Training 
was conducted in a transparent acrylic chamber (110 mm × 160 mm ×  
160 mm/110 mm × 135 mm × 155 mm) containing 3 mm stainless steel rod 
floor, spaced 0.5 cm, through which electric foot-shocks could be administered. 
The test chamber was placed inside a sound-attenuated chamber and was 
constantly illuminated (~130 lx). Mice were observed through a window in the 
front wall of the sound-attenuated chamber. Animals were placed in the 
conditioning context for 120 s and were then exposed to a CS for 30 s. The CS 
was terminated by a US. 120 s later another CS–US pairing was presented. The 
mouse was removed from the chamber 15–30 s later and returned to its home 
cage (Luuk et al., 2009). 
The mice were tested for contextual memory 24 h later by placing them back 
into the test chamber for 5 min with no CS applied. Total time of freezing 
(defined as the absence of any movements for more than 3 s) was measured 
using the standard 10 s interval sampling procedure. Four hours later the mouse 
was tested for freezing behaviour to the auditory CS. Testing was performed in 
a different acrylic chamber (220 mm × 160 mm × 160 mm/220 mm × 135 mm × 
155 mm) the floor of which was covered with white cardboard. The background 
colour was black. Duration of the test was 6 min: 3 min without the tone (pre-
CS phase) and 3 min with the tone (CS phase). Freezing was counted during the 
CS phase. Additionally, the number of rearings in pre-CS and CS periods was 
recorded (Luuk et al., 2009). 
 
Hyponeophagia test 
The experiment was carried out in a brightly lit (~400 lx) room. The mice, food-
deprived for 24 h, were taken from their home cage and placed singly in a 
translucent plastic box (18 cm × 22 cm × 14 cm) filled with a single layer of 
food pellets (Lactamin AB, Sweden; weighing 1.5–3.5 g) to a depth of 
approximately 1 cm. To avoid social transmission of behaviour, mice that had 
already been tested were placed in a separate box. The latency to start eating 
was measured from the time a mouse was placed in the box. Eating was defined 
as eating for at least 3 s consecutively. A cut-off score of 180 s was used (Luuk 
et al., 2009). 
 
Forced swimming test 
Mice were placed for 6 min into a glass cylinder (diameter 12 cm, height 24 cm, 
water depth 15 cm) filled with 25 ± 0.5 °C fresh tap water. A 5 s standard 
interval sampling technique was used for rating behaviour (Cryan et al., 2002) 
during the last 4 min of the test. Specific behavioural components were 
distinguished: (1) climbing behaviour, defined as upward-directed movements 
of the forepaws along the side of the swim chamber; (2) swimming behaviour, 
the horizontal movement throughout the swim chamber; (3) immobility, defined 
as no activity other than that required to keep the animal’s head above water 
(Luuk et al., 2009). 
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Morris water maze test 
Spatial memory was studied in Morris water maze (TSE Technical & Scientific 
Equipment GMBH, Germany). The pool (150 cm in diameter, 50 cm in depth) 
was filled with 22–24 °C water to a depth of 38 cm. Water surface was made 
opaque with the addition of non-toxic fine-grained white putty. The invisible 
white escape platform (16 cm in diameter, submerged 1 cm under water) was 
positioned in the centre of the imaginary Southwest quadrant, 20 cm from the 
wall. It remained in a fixed position during the training. Subjects’ movements 
were recorder by a computer connected to the video camera placed above the 
pool. The experimental room was lighted with four symmetrically placed lamps 
with 25 W light-bulbs and also a table lamp, which filled the room with dim 
light (ca. 20 lx). Coloured flyers and figures on the walls served as spatial cues. 
During each trial, a mouse was released into the water facing the wall of the 
pool from pseudo-randomly chosen cardinal compass points (North, East, South 
and West). Randomization ensured that all positions were sampled before a 
given position was repeated. The acquisition phase of the experiment consisted 
of a series of 20 initial training trials, lasting up to 60 s each with inter-trial 
interval of approximately 1 h (five trials per day on 4 consecutive days) and 12 
reverse training trials (six trials per day on 2 days). A 60 s probe trial without 
the platform was performed at the end of each training cycle, 1 h after the last 
training trial. In probe trials, mice were released at a location on the opposite 
side of where platform had been located (on day 4 from Northeast, on day 6 
from Southwest). For statistical purposes, the reversal training sessions were 
divided into four blocks of three trials. In all trials, mice were allowed to swim 
until they landed on the platform or until 60 s had elapsed. Mice failing to find 
the platform within 60 s were gently placed on the platform with a metal escape 
sieve and left there about 15 s to orient. Mice that found the platform were also 
left there for about 15 s. After each trial mice were put to their home cage with 
the escape sieve. Mice quickly learned to associate the sieve with escaping from 
the pool and consistently oriented to or followed the sieve on its appearance. 
The ability of mice to orient to or follow the escape sieve represented indepen-
dent measures of vision and attention. The latency to find the submerged 
platform, the distance travelled, swim velocity and time spent in the periphery 
were registered with water maze software (TSE Technical & Scientific 
Equipment GMBH, Germany) (Luuk et al., 2009). 
 
Active avoidance test 
Active avoidance is a fear-motivated associative avoidance task providing a 
simple way to assess associative learning and memory. In this task the mouse 
has to learn to predict the occurrence of an aversive event (electric foot-shock) 
based on the presentation of a specific stimulus (tone or light), in order to avoid 
the aversive event by moving to a different compartment (Luuk et al., 2009). 
Active avoidance learning was carried out in a rectangular two-way 
automated shuttle-box (TSE), consisting of two similar chambers (14 cm ×  
11 cm × 16 cm) connected by an arched opening (4 cm × 4 cm). The box was 
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surrounded by a soundproof chamber. The apparatus was located in a quiet, 
very dimly (5 lx) illuminated room. The shuttle-boxes had a cover with a light-
bulb (10 W) attached above each compartment. Foot-shocks could be 
administered through a stainless steel rod floor (diameter 3 mm, spaced 5 mm). 
Mice were placed in the dark compartment facing the wall of the chamber and 
submitted to an active avoidance test for four consecutive days, 30 trials a day. 
The test started with a habituation time of 10 s. The conditioned stimulus (CS) 
was a 10 kHz tone with a maximum duration of 20 s accompanied by lighting 
up of the target compartment (light and sound signal). The unconditioned 
stimulus (US; 0.3 mA electrical foot-shock for 5 s) was switched on 5 s after CS 
and was followed by a stronger US (by a 0.6 mA foot-shock for a maximum of 
10 s) in case the mouse failed to move to the target compartment. Intertrial 
interval was 10 s. After 30 trials, mice were taken back to their home cage 
(Luuk et al., 2009). 
 
Testing order of animals 
Only experimentally naïve animals were subjected to the experiments marked 
as first in the testing order (Table 2). We tested all mice several times to reduce 
the number of animals used. Behavioural tests were divided into two categories, 
either sensitive or insensitive to previous experimental experience. Plus-maze, 
forced swimming test, locomotor activity, fear conditioning and hyponeophagia 
were considered as sensitive, whereas stress-induced analgesia, rota-rod test, 
Morris water maze test, active avoidance test and dopamine agonist induced 
hyperlocomotion as insensitive or less sensitive tests (McIlwain et al., 2001; 
Voikar et al., 2004, Luuk et al., 2009). 
 
 
Table 2. Order of behavioural tests 
Behavioural test Number in order 
Elevated plus-maze 1 
Locomotor activity test 1, 2 
Forced swimming test 1 
Hyponeophagia 1 
Fear conditioning 1 
Light-dark box exploration test 2 
Amphetamine-induced hyperlocomotion 2 
Apomorphine-induced hyperlocomotion 3 
Rota-rod test 2 
Active avoidance test 3 
Stress-induced analgesia 4 
Morris water-maze test 3 
Luuk et al., 2009 
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5.4. Evaluation of function of dopaminergic system  
in Wfs1 Deficient mice (Study 3) 
Additionally to impaired glucose metabolism, our preliminary pharmacological 
studies (Study 1) proved the locomotor stimulatory effect of amphetamine, an 
indirect agonist of dopamine (DA), to be significantly weaker in Wfs1-deficient 
mice and these mice exhibited an enhanced locomotor response to apo-
morphine, a direct DA receptor agonist (Luuk et al., 2009). The DA-ergic 
system in Wfs1-deficient mice was studied in terms of 1) the effect of 
amphetamine (5 mg/kg) and apomorphine (3 mg/kg) on locomotor activity and 
DA metabolism, 2) the motor sensitization to the repeated treatment with 
subthreshold dose of amphetamine (2.5 mg/kg), 3) the expression of Dat and 
Drd2 receptor mRNAs, 4) the expression of Dat protein. Therefore, the main 
goal of this study was to establish the possible alterations in the DA-ergic 
system due to the invalidation of the Wfs1 gene in mice. 
The locomotor activity was measures as described above. The distance 
travelled, time in locomotion and number of corner entries were registered. 
Illumination level in the motility boxes during the experiments was appro-
ximately 400 lux. The higher illumination level was used to suppress sponta-
neous locomotor activity in mice. This approach enables one to see the motor 
stimulation at lower doses of dopamine agonists, otherwise being masked with a 
high exploratory activity of animals. In the beginning, animals were habituated 
(30 min) to the motility boxes on two consecutive days. This was done in order 
to reduce any behavioral activation due to novelty seeking. Thereafter the 
animals were tested in the same boxes with saline and drugs (amphetamine 5 
mg/kg, apomorphine 3 mg/kg). Since the behavioral experiments lasted 9 h, 
precautions were taken to control the possible daily fluctuations in the loco-
motor activity of animals. Therefore, the experiments were always performed in 
randomized order, that is, wild-type mice were always used in parallel with 
genetically modified animals. Sensitization of animals to amphetamine was also 
measured using the same motility boxes with similar environmental conditions. 
For this, the animals were habituated for two days and on the third day the 
experiment started. Animals were injected with 2.5 mg/kg amphetamine, and 
placed into the motility boxes for 30 min once a day for 6 consecutive days 
(Visnapuu et al., 2013). 
 
 
5.5. Biochemical measurements 
Blood glucose measurement and glucose tolerance test 
Non-fasted experimentally naïve animals were used for this experiment. In 
order to reduce the behavioural stress due to the repeated handling, the animals 
were kept in their home cages. Blood samples were collected by repeated tail 
vein punctures from mice immobilized in a 50 ml tube restrainer. Intraperi-
toneal injection of D(+)-glucose (Sigma, 2 g/kg, dissolved in saline) was per-
formed after the first glucose measurement (at 0 min). Additional blood samples 
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were taken 30, 60 and 120 min after the injection. Blood glucose concentration 
was measured using Accu-Check GO portable glucometer (Roche, Mannheim, 
Germany) (Luuk et al., 2009). 
 
Corticosterone response to stress 
The study was performed between 12:00 and 14:00. An equivalent number of 
group-housed experimentally naïve animals received either an i.p. injection of 
saline (stress treatment group) or were left undisturbed in their home cage until 
decapitation in a separate room after 30 min. Immediately after decapitation, 
blood from the trunk of the body (mixed arterial and venous blood) was 
collected into heparinized tubes and centrifuged for 10 min at 1500 × g. Sera 
were stored at −20 °C until the assay using corticosterone HS ELISA kit Octeia 
from Immunodiagnostic Systems (U.K.) according to manufacturer’s instruc-
tions. Briefly, 400 μl of buffer was added to 100 μl of calibrator, control or 
sample serum, followed by 30 min incubation at 80 °C and cooling to the room 
temperature. One hundred microliters of heat-treated calibrator, control or 
sample were transferred to antibody-coated plates and 100 μl of enzyme con-
jugate was added. Plate was covered and incubated at 22 °C for 4 h, then 
washed three times with wash buffer. Next, 200 μl of TMB substrate was added 
and incubated at 22 °C for 30 min. Absorbance was measured at 450 nm after 
adding 100 μl of stop solution (Luuk et al., 2009). 
 
Monoamine measurements 
Mice were randomly divided into groups that received an injection of only 
saline, amphetamine (5 mg/kg) or apomorphine (3 mg/kg). After administration 
of saline or DA agonists the animals were placed into the above described 
motility boxes where their locomotor activity was assessed. This procedure 
lasted 30 min after which the mice were decapitated and their brains rapidly 
removed. There was also one group of mice taken directly from their home-
cages in order to measure the effect of exposure of mice to the motility boxes. 
Two brain regions were dissected – the dorsal (encompassing the caudate 
putamen) and ventral striatum (encompassing the nucleus accumbens and 
olfactory tubercle) – and frozen in liquid nitrogen. The dissection was per-
formed according to the coordinates presented in the mouse brain atlas by 
Franklin and Paxinos (Franklin and Paxinos 1997). DA and its metabolites were 
assayed by high performance liquid chromatography (HPLC) with electro-
chemical detection. The tissue samples were homogenized with Bandelin Sono-
puls ultrasonic homogenizer (Bandelin Electronic, Berlin, Germany) in ice-cold 
solution of 0.1 M perchloric acid (10–30 μl/mg) containing 5 mM sodium 
bisulphite and 0.4 mM EDTA to avoid oxidation. The homogenate was then 
centrifuged at 17,000 × g for 10 min at 4 °C. Aliquots (10 μl) of the obtained 
supernatant were chromatographed on a Lichrospher 60 RP Select B column 
(250 × 3 mm; 5 μm). The separation was done in isocratic elution mode at 
column temperature of 30 °C using the mobile phase containing 0.05 M sodium 
citrate buffer at pH 3.7; 0.02 mM EDTA; 1 mM KCl; 1 mM sodium octyl-
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sulphonate and 5.6% acetonitrile. The chromatography system consisted of a 
Hewlett Packard HP 1100 Series isocratic pump, a thermostated autosampler, a 
thermostated column compartment and an HP 1049 electrochemical detector 
(Agilent, Waldbronn, Germany) with glassy carbon electrode. The measure-
ments were done at an electrode potential of + 0.7 V versus the Ag/AgCl 
reference electrode. We measured the tissue levels of dopamine (DA) and its 
metabolites – 3 methoxytyramine (3-MT), 3,4- dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) in pmol/mg of tissue weight. Finally, 
DA turnover was calculated as the ratio between the tissue levels of DA 
endmetabolite HVA and DA itself (HVA/DA) (Visnapuu et al., 2013) 
 
 
5.6. Gene expression studies 
Gene expression studies of GABA-related genes in WSF1 deficient mice 
(Study 2) 
In the study 1 we have found that the genetic invalidation of Wfs1 gene exon 8 
impairs the adaptation of mice in a novel and stressful environment in terms of 
increased anxiety in ethological models. Pre-treatment of mutant mice with 
diazepam (1 mg/kg), an anxiolytic drug acting via GABAA receptors, anta-
gonized increased anxiety (in elevated plus-maze test) and stress-induced 
vocalizations in Wfs1-deficient mice (Luuk et al., 2009). As the pharmacolo-
gical action of diazepam is to enhance the effect of the neurotransmitter GABA 
by binding to the benzodiazepine site on the GABAa receptor the expression of 
Gabra1 and Gabra2 (coding alpha 1 and alpha 2 subunits of GABA receptors) 
genes was studied in the frontal cortex, temporal lobe, hippocampus and meso-
limbic area. All these brain areas show high concentrations of Wfs1 protein and 
mRNA (Luuk et al., 2008, Luuk et al., 2009). To determine the overall impact 
of Wfs1 deficiency for GABA-ergic system, the expression of Gad1 and Gad2 
genes, enzymes responsible for the synthesis of GABA, were studied in the 
temporal lobe and frontal cortex. 
The behavioral experiments lasted from 10 a.m. to 3 p.m. and were per-
formed in two separate rooms. In the first room the elevated plus-maze experi-
ment was performed and in the second room animals were decapitated for 
dissection of brain structures. The elevated plus-maze test was carried out as 
described above. Before testing in the elevated plus-maze, animals were kept in 
isolation for 15 min. According to our previous experience, short-term isolation 
of mice increases their exploratory activity. During a 5-min observation session 
the following measures were taken: (1) the number of closed and open arm 
entries, (2) time spent in exploring the open arms and (3) the number of head-
dipping and stretch-attend postures. Subsequently, the ratio between open and 
total arm entries was calculated. Testing began by placing an animal on the 
centre of the elevated plus-maze facing the closed arm. An arm entry was 
counted only when all four limbs of a mouse were within a given arm (Raud et 
al., 2009). 
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Experimentally naïve animals and animals exposed to the elevated plus-
maze, belonging to both genotypes, were used in parallel. Mice were deca-
pitated immediately after the elevated plus-maze exposure or taking them out 
from the home-cage. Brains were quickly dissected into four parts (the frontal 
cortex, mesolimbic area [including the nucleus accumbens and olfactory 
tubercle], hippocampus and temporal lobe [including the amygdala]) and frozen 
in liquid nitrogen. The brain dissection was performed according to the 
coordinates presented in the mouse brain atlas (Franklin and Paxinos 1997). 
Total RNA was extracted individually from each brain structure of each mouse 
using Trizol® Reagent (Invitrogen, USA) according to the manufacturer’s 
protocol. First strand cDNA was synthesized by using poly (T)18 oligo-
nucleotides and SuperScript™ III Reverse Transcriptase (Invitrogen, USA). The 
quantitative real-time PCR (qRT-PCR) experiment for Gabra1 and Gabra2 
expression studies was performed using SYBR Green. SYBR® Green techno-
logy was chosen, because these primers were previously designed and opti-
mized for this method in our other study (Sütt et al., 2008). The primers used 
are presented in Table 3 (Raud et al., 2009). 
 
 
Table 3. The primers used for analysis of GABA-ergic genes 
Gene symbol Assay ID or sequence Gene ID 
Gabra1 forward 5’-TGTACACCATGAGGTTGACCGT-3’, NM 919250.3 
Gabra 1 reverse 5’-GAAGTCTTCCAAGTGCATTGGG-3’ NM 919250.3 
Gabra 2 forward 5’-ATGGTCTCTGCTGCTTGTTCTTCT-3’ NM 008066 
Gabra 2 reverse 5’-AGCACCAACCTGACTGGGTC-3’ NM 008066 
Hprt forward 5’-GCAGTACAGCCCCAAAATGG-3’  
Hprt reverse 5’-AACAAAGTCTGGCCTGTATCCAA-3’  
Raud et al., 2009. 
 
 
For Gad1 (ID: NM 008077)  and Gad2 (ID: 008078) gene expression, Taqman 
assays Mm00725661_s1 and Mm01329282_m1 (Applied Biosystems) were 
used, respectively. In order to select the most stably expressed reference gene 
we used pairwise comparison approach developed by Vandesompele (Vande-
sompele et al., 2002). This approach top ranks the candidates with the highest 
degree of similarity of the expression profile across the sample set. In the 
present study three candidate normalization genes, HPRT1, GAPDH, B2M (β2 -
microglobulin), were used as they are considered the most common used 
housekeeping genes expressed in brain tissues. The amplification efficiency of 
the reference genes was as follows: HPRT1 96%, GAPDH 67% and B2M 92%. 
The intra-assay coefficient of variability for B2 M, GAPDH and HPRT1 genes 
was 0.62%, 0.11% and 0.06%, respectively. The inter-assay variability for B2 
M, GAPDH and HPRT1 was 3.4%, 2.3% and 2%, respectively. According to 
the internal gene-stability measure (M) of the candidate gene the most stable 
genes were HPRT1 (M = 0.013) and GAPDH (M = 0.014). The M value for B2 
M was 0.022. However, since the amplification efficiency of HPRT1 was 
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higher compared to GAPDH and also it was equal to the amplification effi-
ciency on target genes Gabra1 and Gabra2 (data not shown), we chose HPRT1 
as the housekeeper for the real-time PCR analysis. Another argument for 
selecting HPRT1 was the fact that [Ct] for GAPDH resulted in higher value 
between the target and reference gene and this makes following comparison 
between groups not so effective as in case of HPRT1, because a higher value 
between the target and reference gene gives smaller differences in ratio 
calculation. 
For the Hprt gene, a housekeeping gene, the following primers were used: 
5’-GCAGTACAGCCCCAAAATGG-3’ (forward) and 5’-AACAAAGTCTGG 
CCTGTATCCAA-3’ (reverse). The probe for Hprt was 5’-VIC-AAGCTTG 
CTGGTGAAAAGGACCTCTCG TAMRA-3’ (Raud et al., 2009) 
 
Gene expression studies of dopamine-related gened in Wfs1 deficient mice 
(Study 3) 
This study was done on a separate group of animals taken directly from their 
home-cages. The gene expression studies in wild-type, heterozygous and homo-
zygous animals were conducted in parallel. The measurements were performed 
on the midbrain for dopamine transporter and the dorsal and ventral striatum for 
dopamine D2 receptors(Drd2). For qRT-PCR analysis, the ABI PRISM 7900HT 
Fast Real-Time PCR System equipment (PE Applied Biosystems, USA) and the 
ABI PRISM 7900 SDS 2.2.2 Software were used. Every reaction was made in 
four parallel samples to minimize possible errors. All reactions were performed 
in a final volume of 10 μl, using 50–100 ng of cDNA. Taqman assays (PE 
Applied Biosystems) for genes are given in Table 3 (Visnapuu et al., 2013). 
 
 
Table 4. The Taqman assays and probes used in the study 
Gene symbol Assay ID or sequence Gene ID 
Slc6a3 (dat)  Mm00438396_m1 NM_010020  
Drd2 Mm00438545_m1 NM_010077.2 
Hprt1 for 5’-GCAGTACAGCCCCAAAATGG-3’  






Visnapuu et al., 2013 
 
 
5.7.  Western blot 
As in the case of gene expression study, the protein measurements were per-
formed on a separate group of animals taken directly from their home-cages. 
Brains were removed and the dorsal and ventral striatum dissected. Protein 
extraction was performed using the PARIS kit (Life Technologies) supple-
mented with Protease inhibitor cocktail (Thermo Scientific) as described by 
Raida et al. (2012). The tissues were sonicated and centrifuged for 10 min 
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12,000g at 4°C. The supernatants were kept on –80°C and the protein con-
centrations were measured by BCA method. Reagents and equipment for 
electrophoreses and protein transfer was used according to manufacture’s guide-
lines regarding the NuPAGE system (Life Technologies) and described in detail 
in Raida et al. 2012. For western blotting, membranes were blocked for one 
hour in 3% BSA in PBS. Following blocking the membranes were incubated 
with rat anti-Dat (Santa Cruz Biotechnologies cat# sc- 32258 in 1:1,000 
dilution) and rabbit anti-ß-actin (Cell Signaling cat# 4970 in 1:15,000 dilution) 
overnight at 4°C. After primary antibody incubation the membranes were 
washed 6 times in Milli-Q water and incubated with Alexa 680-conjugated 
donkey anti-rat and Alexa-790 conjugated donkey anti-rabbit (Jackson Immuno 
Research cat# 712-625-150 and 711-655-152 in 1:20,000 dilution) for one hour 
at RT. After secondary incubations the membranes were washed 6 times in 
Milli-Q water followed by a 20 min wash step in PBS-0,1% Tween-20. Prior to 
signal detection the membranes were washed 6 times in Milli-Q water. Anti-
body detection was performed using the Li-Cor Odyssey CLx system (Li-Cor 
biotechnologies). Images were converted to grayscale and quantification was 
performed using the Gel-analyzer plugin in ImageJ following NIH guidelines 
(Visnapuu et al., 2013). 
 
 
5.8. Statistics and analysis of results 
Mean values and S.E.M. are presented in the figures and tables. All data were 
analyzed using Statistica version 8.0 (StatSoft, Inc., USA). Behavioural studies 
and corticosterone measurements were analysed using one-way or two-way 
analysis of variance (ANOVA). Two-way mixed design ANOVA was applied 
to data from glucose tolerance test (genotype, between-subjects × time, within 
subjects) and fear conditioning studies (genotype, between-subjects × tone, 
within subjects). Data from studies of locomotor activity as well as the learning 
curves in active avoidance and Morris water maze tests were analysed by 
repeated measures ANOVA. Genotype was a between-subjects variable in all 
ANOVA analyses. Data from forced swimming test was analysed with non-
parametric Mann–Whitney U-test. Data from hyponeophagia, rota-rod test and 
context-dependent experiments in fear conditioning paradigm were analysed 
with Student’s t-test. A three way repeated measures ANOVA (genotype x 
treatment x day) was used in the experiment measuring sensitization to 
amphetamine. The plus-maze studies for evaluation of GABA-related gene 
expression were analyzed by means of Student’s t-test for independent samples. 
As our goal was to compare the effect of the plus-maze exposure and genetic 
manipulation on the expression of GABA-related genes, the only acceptable 
way to test the validity of this approach was application of two-way ANOVA 
(genotype and plus-maze exposure as independent variables). Two-way 
ANOVA (genotype and treatment as independent measures) was performed in 
the experiments measuring the locomotor activity and brain dopamine levels. 
One-way analysis of variance (ANOVA) was applied in the dopamine-related 
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gene expression experiments and Mann-Whitney U test was used for the protein 
expression studies. Post hoc comparisons between individual groups were 
performed using either Newman–Keuls or Tukey HSD test (Luuk et al., 2009, 
Raud et al., 2009, Visnapuu et al., 2013) 
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6. RESULTS 
6.1. Study 1: Description of behavioral phenotype  
of Wfs1 deficient mice  
 
Reproduction and overt appearance 
Analysis of reproduction rates of Wfs1-deficient mice during 5 months in late 
2007 and early 2008 (a total of 526 births was recorded during the period) 
indicated an approximately 5% lower birthrate of homozygous Wfs1-deficient 
mice than expected (20.8% of all females, 21.8% of all males). In general, 
homozygous Wfs1-deficient mice were normal in overt appearance, but 
occasionally very small individuals (weighing around 15 g at 3 months of age) 
were present in the male population. The most peculiar aspect of the overt 
phenotype of homozygous Wfs1-deficient population was the presence of 
individuals producing spontaneous audible vocalizations in the 10 kHz range. 
The proportion of such individuals varied across different batches from around 
15 to 50%, and was comparable in males and females. The vocalizations can be 
described as “chirps” with a fundamental frequency of 3.1 kHz and prominent 
harmonics at 6.2 and 9.3 kHz (Fig. 4). It was noted that the number of mice 
producing audible vocalizations was higher under stressful conditions (bright 
light, handling/injection stress), that the temporal frequency of these calls could 
get as high as five times per second, and that the calls could vary in loudness. 
Additionally, in most individuals, calling was blocked by the administration of 





Figure 4. Sonogram of audible vocalizations produced by homozygous Wfs1-deficient 
mice (Luuk et al., 2009). 
 
 
Body weight and glucose tolerance test 
In the first batch of 2- and 3-month-old female mice, significantly lower body 
weight was found in homozygous Wfs1-deficient mice when compared to wild-
type littermates (Fig. 5A) (F(1, 105) = 60.8, p < 0.001 (genotype); F(1, 105) = 
7.9, p < 0.01 (age, between-subjects); F(1, 105) = 2.46, p = 0.12 (genotype × 
age)). In contrast to wild-types, there was no significant body weight difference 
between 2- and 3-month-old Wfs1-deficient mice. In a different batch of mice, 
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significant body weight difference between female homozygous Wfs1-deficient 
and wild-type mice was established only at 4 months of age (Fig. 5B). Weight 
gain between 2 and 4 months of age was more pronounced in wild-type and 
heterozygous Wfs1-deficient mice when compared to homozygous mice (F(2, 
27) = 6.7, p < 0.01 (genotype); F(1, 27) = 11.9, p < 0.01 (age, within-subjects); 





Figure 5. Lower body weight in female homozygous Wfs1-deficient mice. (A) Body 
weight of wild-type (white bars) and homozygous Wfs1-deficient mice (black bars) at 2 
and 3 months of age. *p < 0.05 (compared to wild-type mice of respective age; 
Newman–Keuls test after significant two-way ANOVA); +p < 0.05 (compared to wild-
type mice at 2 months of age). Number of mice in groups ranged from 22 to 30. (B) 
Weight gain in wild-type (white bars), heterozygous (hatched bars) and homozygous 
(black bars) Wfs1-deficient mice. *p < 0.05 (compared to wild-type mice of respective 
age; Newman–Keuls test after significant repeated measures ANOVA). Number of mice 
in each group was 10 (Luuk et al., 2009). 
 
 
Baseline blood glucose levels did not differ between non-fasted wild-type, 
heterozygous and homozygous Wfs1-deficient mice (Fig. 6). Intraperitoneal 
administration of glucose elevated blood glucose levels only in heterozygous 
and homozygous Wfs1-deficient mice (F(2, 27) = 154.4, p < 0.001 (genotype); 
F(3, 27) = 81.5, p < 0.001 (time, within-subjects); F(6, 27) = 23.5, p < 0.001 
(genotype × time)). Compared to the baseline, in homozygous mice, the 
concentration of blood glucose was significantly higher at 30 and 60 min (p < 
0.001), and in heterozygous mice at 30 min (p < 0.001) after the administration 





Figure 6. Intolerance to intraperitoneal glucose in non-fasted Wfs1-deficient mice. The 
experiment was performed in female mice. Blood glucose concentration after i.p. admi-
nistration of glucose (2 g/kg). White bars, wild-type mice; hatched bars, heterozygous 
Wfs1-deficient mice; black bars, homozygous Wfs1-deficient mice. *p < 0.05 (com-
pared to wild-type mice at respective time point; Newman–Keuls test after significant 
repeated measures ANOVA); **p < 0.001. Number of mice in each group was 10 (Luuk 
et al., 2009). 
 
 
Stress-induced changes in corticosterone levels 
No differences in mean blood plasma corticosterone levels were detected in 
unstressed individuals of different genotypes (Fig. 7). Stress induced by 
handling and injection of saline induced a significantly larger increase in the 
plasma corticosterone concentration in female homozygous Wfs1-deficient 
mice (p < 0.05) when compared to their wild-type littermates (Fig. 7)  
(F(1, 12) = 30.9, p < 0.001 (genotype); F(1, 12) = 128.8, p < 0.001 (injection, 




Figure 7. Stress induces higher levels of plasma corticosterone in female Wfs1-
deficient mice. White bars, wild-type mice; black bars, homozygous Wfs1-deficient 
mice. *p < 0.05 (compared to unstressed individuals of respective genotype; Newman–
Keuls test after significant two-way ANOVA); +p < 0.05 (compared to respective group 
of wild-type mice). Number of mice in each group was 4 (Luuk et al., 2009). 
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Stress-induced analgesia 
In both, wild-type and homozygous Wfs1-deficient mice, the degree of anal-
gesia was dependent on the intensity of electric foot-shocks (Fig. 8) (F(3, 77) = 
54.4, p < 0.001 (stress, between-subjects)). Foot-shocks of intermediate inten-
sity (0.4 mA) induced a significantly stronger analgetic response in 
homozygous Wfs1-deficient mice compared to their wild-type littermates (F(1, 
77) = 5.5, p < 0.05 (genotype); F(3, 77) = 3.3, p < 0.05 (genotype × stress)) 




Figure 8. Stress-induced analgesia in female Wfs1-deficient mice. White bars, wild-
type mice; black bars, homozygous Wfs1-deficient mice. *p < 0.05 (compared to 
unstressed littermates of respective genotype; Newman–Keuls test after significant two-
way ANOVA); +p < 0.05 (compared to respective group of wild-type animals). Number 




Performance of wild-type (119 ± 1 s; n = 19) and homozygous Wfs1-deficient 
mice (110 ± 7 s; n = 20) was statistically not different in the rota-rod test  (Luuk 
et al., 2009). 
 
Locomotor activity in dim and bright environments 
Locomotor activity of wild-type and homozygous Wfs1-deficient mice was 
compared in a dimly (~20 lx) and brightly (~450 lx) lit room (Fig. 9). Exposure 
of mice to bright light decreased all locomotor activity parameters in both 
genotypes in relation to the dim environment (time in locomotion: F(1, 37) = 
116.1, p < 0.001 (environment, within-subjects)); distance travelled: F(1, 37) = 
93.4, p < 0.001; time spent in the centre: F(1, 37) = 39.5, p < 0.001; number of 
rearing: F(1, 37) = 17.1, p < 0.001). In the dark room, homozygous Wfs1-
deficient mice made significantly less rearings (p < 0.05) while the other 
parameters were similar in the genotypes. Locomotor activity was significantly 
lower in Wfs1-deficient mice under bright light (time in locomotion: F(1, 37) = 
10.6, p < 0.01 (genotype); F(1, 37) = 1.87, p = 0.18 (genotype × environment); 
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distance travelled: F(1, 37) = 8.1, p < 0.01 (genotype); F(1, 37) = 1.70, p = 0.20 
(genotype × environment); number of rearing: F(1, 37) = 7.3, p < 0.05 






Figure 9. Lower exploratory activity in female Wfs1-deficient mice at high illumination 
levels. White bars, wild-type mice (n = 20); black bars, homozygous Wfs1-deficient 
mice (n = 19). *p < 0.05 (compared to respective genotype in the dark environment; 
Newman–Keuls test after significant repeated measures ANOVA); +p < 0.05 (compared 
to respective group of wild-type animals) (Luuk et al., 2009). 
 
 
Effect of amphetamine and apomorphine on locomotor activity 
Administration of amphetamine (2.5, 5 and 7.5 mg/kg) induced a dose-dependent 
activation of locomotor behaviour in female wild-type mice (Fig. 10). The 
stimulatory effect of amphetamine was weaker in heterozygous and homozygous 
Wfs1-deficient mice than in wild-type littermates (time in locomotion: F(2, 27) = 
5.78, p = 0.008 (genotype), F(3, 81) = 109.2, p < 0.001 (treatment, within-
subjects), F(6, 81) = 0.57, p = 0.76 (genotype × treatment); distance travelled: 
F(2, 27) = 4.1, p < 0.05 (genotype), F(3, 81) = 59.3, p < 0.001 (treatment, within-
subjects), F(6, 81) = 1.12, p = 0.36 (genotype × treatment); number of corner 
entries: F(2, 27) = 3.1, p = 0.06 (genotype); F(3, 81) = 34.7, p < 0.001 (treatment, 
within-subjects); F(6, 81) = 1.05, p = 0.40 (genotype × treatment)). The 
stimulatory effect of intermediate dose of amphetamine (5 mg/kg) on locomotor 
activity was significantly weaker in homozygous Wfs1-deficient mice than in 
wild-type littermates in terms of distance travelled and number of corner entries 
(p < 0.05). By contrast, treatment of the same mice with apomorphine (3 mg/kg) 
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induced significantly higher locomotor activation in female homozygous Wfs1-
deficient mice when compared to the other genotypes (time in locomotion: F(2, 
27) = 5.62, p < 0.01 (genotype), F(1, 27) = 29, p < 0.001 (treatment, within-
subjects), F(2, 27) = 0.89, p = 0.42 (genotype × treatment); distance travelled: 
F(2, 27) = 5.62, p < 0.01 (genotype), F(1, 27) = 27.3, p < 0.001 (treatment, 
within-subjects), F(2, 27) = 0.54, p = 0.59 (genotype × treatment); number of 
corner entries: F(2, 27) = 3.74, p < 0.05 (genotype), F(1, 27) = 44.6, p < 0.001 
(treatment, within-subjects), F(2, 27) = 0.18, p = 0.83 (genotype × treatment)). A 
gene dose effect of Wfs1 was apparent for all parameters presented in Fig. 10 




Figure 10. Differential sensitivity of female Wfs1-deficient mice to the locomotor stimulatory 
effects of amphetamine (2.5, 5 and 7.5 mg/kg) and apomorphine (3 mg/kg). White bars, wild-type 
mice; hatched bars, heterozygous Wfs1-deficient mice; black bars, homozygous Wfs1-deficient 
mice. *p < 0.05 (compared to saline-treated mice of respective genotype; Newman–Keuls test 
after significant repeated measures ANOVA); +p < 0.05 (compared to respective group of wild-
type animals). Number of animals in each group was 10 (Luuk et al., 2009). 
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Effect of short-term isolation on behaviour in light-dark box exploration test 
The exploratory activity of non-isolated wild-type and homozygous Wfs1-
deficient mice was not different in the light-dark box exploration test (Fig. 11). 
By contrast, short-term isolation induced a significant suppression of explora-
tory behaviour only in Wfs1-deficient mice. Wfs1-deficient mice made less 
transitions between the two compartments (F(1, 42) = 8.40, p < 0.01 (geno-
type); F(1, 42) = 0.96, p = 0.33 (isolation, between-subjects); F(1, 42) = 2.99,  
p = 0.09 (genotype × isolation)) and spent less time in the light compartment as 
compared to wild-type littermates (F(1, 42) = 9.32, p < 0.01 (genotype); F(1, 
42) = 3.41, p = 0.07 (isolation, between-subjects); F(1, 42) = 0.92, p = 0.34 





Figure 11. Anxiety-like behaviour in Wfs1-deficient mice in light-dark box exploration 
test. White bars, wild-type mice; black bars, homozygous Wfs1-deficient mice. *p < 
0.05 (compared to isolated wild-type mice; Newman–Keuls test after significant two-
way ANOVA). Number of animals in groups ranged from 11 to 12 (Luuk et al., 2009). 
 
 
Effect of diazepam in elevated plus-maze 
Vehicle-treated homozygous Wfs1-deficient mice displayed lower exploratory 
activity when compared to vehicle-treated wild-types (Fig. 12). Specifically, the 
percentage of open arm entries and the number of head-dippings was signifi-
cantly lower in Wfs1-deficient mice (Newman–Keuls test, p < 0.05). A similar, 
albeit not statistically significant, trend was observed for the number of open 
arm entries and time spent on open arms. Additionally, the number of in-
complete attempts to enter the central platform, a measure of risk assessment 
behaviour (Nelovkov et al., 2006), was significantly higher in homozygous 
Wfs1-deficient mice when compared to wild-type littermates. Exploratory 
activity of wild-type mice was not affected by the administration of diazepam (1 
mg/kg). In Wfs1-deficient mice, the administration of diazepam caused a robust 
anxiolytic-like effect as evidenced by increased number of open arm entries 
(F(1, 60) = 0.01, p = 0.99 (genotype); F(1, 60) = 6.19, p < 0.01 (treatment, 
between-subjects); F(1, 60) = 3.72, p < 0.05 (genotype × treatment)), increased 
time spent on open arms (F(1, 60) = 0.46, p = 0.50 (genotype); F(1, 60) = 6.18, 
p < 0.01 (treatment, between-subjects); F(1, 60) = 2.75, p = 0.10 (genotype × 
treatment)), increased percentage of open arm entries from total arm entries 
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(F(1, 60) = 0.18, p = 0.67 (genotype); F(1, 60) = 6.08, p < 0.05 (treatment, 
between-subjects); F(1, 60) = 4.65, p < 0.05 (drug × treatment)), increased 
number of head-dippings (F(1, 60) = 9.16, p < 0.01 (genotype); F(1, 60) = 3.44, 
p = 0.06 (treatment, between-subjects); F(1, 60) = 2.30, p = 0.13 (genotype × 
treatment)) and decreased number of incomplete attempts to enter the central 
platform (F(1, 60) = 2.08, p = 0.15 (genotype); F(1, 60) = 5.31, p < 0.05 
(treatment, between-subjects); F(1, 60) = 1.28, p = 0.26 (genotype × treatment)) 




Figure 12. Anxiolytic effect of diazepam (1 mg/kg) on exploratory behaviour of female 
Wfs1-deficient mice in the elevated plus-maze test. White bars, wild-type mice; black 
bars, homozygous Wfs1-deficient mice. *p < 0.05 (compared to vehicle-treated wild-
type mice; Newman–Keuls test after significant two-way ANOVA); +p < 0.05 (com-
pared to vehicle-treated Wfs1-deficient mice). Number of animals in each group was 16 
(Luuk et al., 2009). 
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Fear conditioning test 
Homozygous Wfs1-deficient and wild-type mice exhibited comparably low 
freezing behaviour in the pre-conditioning test (no freezing in wild-type and 
two freezing episodes in Wfs1-deficient mice). Both genotypes exhibited 
normal contextual memory after conditioning by increased freezing in the 
absence of the conditioned stimulus (Fig. 13A). However, in the Wfs1-deficient 
mice, there was also a tendency towards the reduced number of rearings 
compared to wild-type littermates (Student’s t-test, p < 0.05). When transferred 
to a new context, both, freezing behaviour and rearing were similar to that 
observed in the pre-conditioning session (Fig 13B). Testing of cued fear by 
presenting the conditioned stimulus in the novel context produced a significant 
increase in freezing behaviour (F(1, 66) = 1.57, p = 0.21 (genotype); F(1, 66) = 
152.1, p < 0.001 (conditioned stimulus, within-subjects); F(1, 66) = 0.42, p = 
0.52 (genotype × conditioned stimulus)) and a decrease in rearing (F(1, 66) = 
8.02, p < 0.01 (genotype); F(1, 66) = 30.6, p < 0.001 (conditioned stimulus, 
within-subjects); F(1, 66) = 10.3, p < 0.01 (genotype × conditioned stimulus)) 
in both genotypes. Reduction in the number of rearings upon CS presentation 
was statistically significant only in wild-type mice (p < 0.05). While there was a 
tendency towards reduced rearing in Wfs1-deficient mice in the cued situation, 
floor-effect is a likely explanation of it not reaching statistical significance 





Figure 13. Contextual and cue-dependent responses in female Wfs1-deficient mice in 
fear conditioning test. (A) Contextual fear. White bars, wild-type mice; black bars, 
homozygous Wfs1-deficient mice. *p < 0.05 (compared to wild-type mice, Student’s t-
test). (B) Cued fear. White bars, wild-type mice in new context; striped bars, wild-type 
mice exposed to cued signal in new context; black bars, homozygous Wfs1-deficient 
mice in new context; hatched bars, homozygous Wfs1-deficient mice exposed to cued 
signal in new context. *p < 0.05 (compared to same mice in non-cued situation; 
Newman–Keuls test after significant repeated measures ANOVA); +p < 0.05 (compared 
to wild-type mice in non-cued situation). Thirty-four wild-type and 33 Wfs1-deficient 





Latency to start eating was significantly longer (Student’s t-test, p < 0.05) in 
homozygous Wfs1-deficient mice (162 ± 8 s; n = 19) when compared to wild-
type littermates (135 ± 10 s; n = 19) (Luuk et al., 2009). 
 
Forced swimming test 
The number of mice was 19 for wild-type and 20 for Wfs1-deficient mice. 
Forced swimming did not reveal statistically significant differences between 
wild-type and homozygous Wfs1-deficient mice. For the following parameters 
the values (in seconds) for wild-type and Wfs1-deficient mice were, respec-
tively: 39 ± 1.3 and 36 ± 2.4 (immobility), 5.2 ± 0.6 and 8.7 ± 2.4 (swimming), 
3.9 ± 1.2 and 2.9 ± 1.3 (climbing) (Luuk et al., 2009). 
 
Morris water maze test 
When compared to wild-type littermates, Wfs1-deficient mice displayed overall 
slower swimming speed (F(1, 37) = 8.23, p < 0.01 (genotype); F(3, 111) = 6.0, 
p < 0.001 (trial, within-subjects); F(3, 111) = 0.19, p = 0.91 (genotype × trial)) 
(Fig. 14). Hence, the distance covered in finding the escape platform was a 
more appropriate measure of the learning effect than escape latency. The 
distances to find the platform during the initial training were as follows. Day 1: 
879 ± 55 cm (wild-type) vs. 749 ± 51 cm (Wfs1-deficient); day 2: 434 ± 46 cm 
(wild-type) vs. 475 ± 57 cm (Wfs1-deficient); day 3: 300 ± 49 cm (wild-type) 
vs. 367 ± 57 cm (Wfs1-deficient); day 4: 177 ± 23 cm (wild-type) vs. 300 ±  
43 cm (Wfs1-deficient). There was a significant learning effect in terms of 
swimming distance in both genotypes (day 1 vs. day 4: p < 0.001), but no effect 
of genotype on the swimming distance (F(1, 37) = 0.42, p = 0.52 (genotype); 
F(3, 111) = 58.0, p < 0.001 (trial, within-subjects); F(3, 111) = 2.73, p < 0.05 
(genotype × trial)). Additionally, both wild-type and Wfs1-deficient mice 
displayed significant learning effect by spending more time in the target 
quadrant in the probe trial on day 4 (Fig. 15A) (F(1, 148) = 0.001, p = 0.99 
(genotype); F(3, 148) = 87.3, p < 0.001 (quadrant, within-subjects); F(3, 148) = 
2.83, p < 0.05 (genotype × quadrant)). However, wild-type mice spent more 
time in the target quadrant than their Wfs1-deficient littermates (p < 0.05). A 
significant learning effect was observed in both genotypes also after reversal 
training as evidenced by preference for the new target quadrant in probe trial on 
day 6 (Fig. 15B). However, in reversal training, Wfs1-deficient mice covered 
longer distances when searching for the platform (Fig. 14) (F(1, 37) = 11.4, p < 
0.01 (genotype); F(3, 111) = 51.4, p < 0.001 (trial, within-subjects); F(3, 111) = 





Figure 14. Morris water maze: distance travelled and swimming speed. White bars, 
wild-type mice; black bars, homozygous Wfs1-deficient mice. *p < 0.05 (compared to 
the first trial of respective genotype, Newman–Keuls test after significant repeated 
measures ANOVA); +p < 0.05 (compared to respective group of wild-type animals). 
Nineteen wild-type and 20 homozygous Wfs1-deficient mice were used in the test 




Figure 15. Spatial memory of Wfs1-deficient mice in Morris water maze: time spent in 
the four quadrants. (A) Probe trial after initial training (day 4). *p < 0.05 (compared to 
time spent in quadrants 1, 3 and 4; Newman–Keuls test after significant two-way 
ANOVA); +p < 0.05 (compared to wild-type animals). (B) Probe trial after reversal 
training (day 6). *p < 0.05 (compared to time spent in quadrants 1, 2 and 3; Newman–
Keuls test after significant two-way ANOVA). Nineteen wild-type and 20 homozygous 
Wfs1-deficient mice were used in the test (Luuk et al., 2009). 
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Active avoidance test 
Both, wild-type and homozygous Wfs1-deficient mice learned the task of active 
avoidance without significant differences (Fig. 16) (F(1, 36) = 0.58, p = 0.45 
(genotype); F(3, 108) = 12.2, p < 0.001 (trial, within-subjects); F(3, 108) = 




Figure 16. Conditioned responses of Wfs1-deficient mice in active avoidance test. 
White bars, wild-type mice; black bars, homozygous Wfs1-deficient mice. *p < 0.05 
(compared to the first day of respective genotype, Newman–Keuls test after significant 





6.2. Study 2. Reduced expression of alpha1 and alpha2 
subunits of GABA(A) receptors in Wfs1-deficient mice 
Exploratory behavior of Wfs1 deficient mice in elevated plus-maze 
In the plus-maze test Wfs1-deficient mice displayed increased anxiety-like 
behavior in terms of increased open arm avoidance and affected risk assessment 
behaviors. Homozygous animals made significantly less open arm entries as 
compared to wild-type mice (Student’s t-test, p < 0.05) (Fig. 17). Also, a similar 
tendency was observed for other conventional measures of anxiety: time spent 
on open arms (p = 0.07) and ratio between the open and total arm entries (p = 
0.07). Additionally, the genotype differences were noticeable for the ethological 
measures of anxiety. Namely, Wfs1-deficient mice performed significantly 
more stretch-attend postures compared to their wild-type littermates (p < 0.05) 
(Fig. 17). The number of head-dippings was also reduced, but remained 






Figure 17. Exploratory behavior of Wfs1-deficient mice in the elevated plus-maze. 
White bars: wild-type mice; black bars: homozygous mice.*p < 0.05 (compared to wild-
type mice, Student’s t-test for independent samples) (Raud et al., 2009). 
 
 
Gene expression studies of Gabra1, Gabra2, Gad1 and Gad2 genes  
Expression of Gabra1 gene was significantly higher if compared to Gabra2 gene 
in the forebrain structures. In the frontal cortex it was 2.7-fold in favor of the 
Gabra1 gene, whereas in the temporal lobe and hippocampus the respective 
differences were 1.8-fold and 1.5-fold. The only exception was the mesolimbic 
area where it was only 1.2-fold in favor of Gabra1 gene. It was also expected 
that the Gad1 gene would be significantly more abundant compared to the Gad2 
gene in the forebrain structures. The respective differences were 15-fold and 13-
fold in the frontal cortex and temporal lobe in favor of the Gad1 gene (Raud et 
al., 2009). 
We established significant genotype as well as genotype and elevated plus-
maze exposure interactions for the Gabra1 and Gabra2 genes in the frontal 
cortex and temporal lobe. Genetic invalidation of the Wfs1 gene induced a 
remarkable reduction of the Gabra1 and Gabra2 genes in the temporal lobe and 
frontal cortex (Fig. 18). This effect was not established in the mesolimbic area 
and hippocampus. The exposure of wild-type mice to the elevated plus-maze 
also reduced the expression level of these genes in the temporal lobe and frontal 
cortex. However, only in the temporal lobe it was statistically significant. The 
exposure of Wfs1-deficient mice to the elevated plus-maze did not cause a 
further reduction in the expression of the Gabra1 and Gabra2 genes compared to 
the experimentally naïve mutant mice. Genetic invalidation of the Wfs1 gene or 
exposure of wild-type mice to the elevated plus-maze did not affect the 
expression of the Gad1 and Gad2 genes in the frontal cortex and temporal lobe 





Figure 18. Effect of Wfs1 gene invalidation and plus-maze exposure on the expression 
of the Gabra1 and Gabra2 genes in the forebrain structures. White bars: wild-type mice; 
stripped bars: wild-type mice exposed to the plus-maze; black bars: homozygous mice; 
hatched bars: homozygous mice exposed to the plus-maze. Frontal cortex – Gabra1: 
F1,28 = 7.09, p = 0.02 (genotype); F1,28 = 2.03, p = 0.17 (plus-maze exposure);  
F1,28 = 3.59, p = 0.07 (genotype × plus-maze exposure). Gabra2: F1,28 = 3.28, p = 
0.03 (genotype); F1,28 = 0.03, p = 0.85 (plus-maze exposure); F1,28 = 6.02, p = 0.02 
(genotype × plus-maze exposure). Mesolimbic area – Gabar1: F1,28 = 0.28, p = 0.60 
(genotype); F1,28 = 1.10, p = 0.30 (plus-maze exposure); F1,28 = 1.27, p = 0.27 
(genotype × plus-maze exposure). Gabar2: F1,28 = 6.80, p = 0.015 (genotype); F1,28 = 
0.34, p = 0.57 (plus-maze exposure); F1,28 = 0.41, p = 0.53 (genotype × plus-maze 
exposure). Temporal lobe – Gabar1: F1,28 = 8.97, p = 0.0058 (genotype); F1,28 = 23.7, 
p = 0.00004 (plus-maze exposure); F1,28 = 9.42, p = 0.0058 (genotype × plus-maze 
exposure). Gabra2: F1,28 = 1.80, p = 0.19 (genotype); F1,28 = 5.57, p = 0.03 (plus-
maze exposure); F1,28 = 5.43, p = 0.03 (genotype × plus-maze exposure). 
Hippocampus – Gabar1: F1,28 = 0.43, p = 0.52 (genotype); F1,28 = 1.18, p = 0.29 
(plus-maze exposure); F1,28 = 0.63, p = 0.43 (genotype × plus-maze exposure). 
Gabar2: F1,28 = 8.01, p = 0.009 (genotype); F1,28 = 0.85, p = 0.37 (plus-maze 





Figure 19. Effect of the Wfs1 gene invalidation and plus-maze exposure on the 
expression of the Gad1 and Gad2 genes in the frontal cortex and temporal lobe. White 
bars: wild-type mice; stripped bars: wild-type mice exposed to the plus-maze; black 
bars: homozygous mice; hatched bars–homozygous mice exposed to the plus-maze. 
Frontal cortex – Gad1: F1,28 = 2.06, p = 0.16 (genotype); F1,28 = 0.82, p = 0.37 (plus-
maze exposure); F1,28 = 0.05, p = 0.82 (genotype × plus-maze exposure). Gad2:  
F1,28 = 0.94, p = 0.34 (genotype); F1,28 = 2.53, p = 0.13 (plus-maze exposure);  
F1,28 = 0.66, p = 0.42 (genotype × plus-maze exposure). Temporal lobe – Gad1:  
F1,28 = 3.73, p = 0.07 (genotype); F1,28 = 0.92, p = 0.35 (plus-maze exposure);  
F1,28 = 0.003, p = 0.95 (genotype × plus-maze exposure). Gad2: F1,28 = 2.63, p = 0.12 
(genotype); F1,28 = 0.32, p = 0.57 (plus-maze exposure); F1,28 = 0.21, p = 0.65 
(genotype × plus-maze exposure) (Raud et al., 2009). 
 
 
6.3. Study 3. Impaired activity of dopaminergic system  
in Wfs1 deficient mice 
Effect of exposure of mice to the motility boxes on dopamine levels  
in the dorsal and ventral striatum 
The levels of DA and its major metabolites were compared in mice exposed to the 
motility boxes for 30 min and in animals taken directly from their home-cages. 
Both female and male mice were used for this study. However, the statistical 
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analysis did not reveal any sex-dependent differences and, therefore, the data 
obtained from the female and male mice were pooled. As in the previous study 
(Luuk et al., 2009), the locomotor activity of homozygous mice tended to be 
lower compared to the other genotypes. However, the application of one-way 
ANOVA did not reveal any statistically significant differences in motor activity 
between the genotypes (data not shown). Exposure of mice to the motility boxes 
caused a statistically significant change in the metabolism of DA in the dorsal and 
ventral striatum (Tables 5a, b). A genotype as well as exposure effect was 
established for homovanillic acid (HVA), a major metabolite of DA, in the dorsal 
striatum (genotype effect: F2,51=3.53, p<0.036; exposure effect: F1,51=34.9, 
p<0.001, genotype x exposure effect: F2,51=0,87, p=0.42 Table 5a). Exposure to 
the motility boxes also changed the ratio between HVA and DA (DA turnover) 
(F1,51=57.0, p<0.001) in the dorsal striatum (Fig. 20). Post hoc analysis (Tukey 
HSD test) established that exposure to the motility boxes induced a significant 
increase in the levels of HVA in wild-type and heterozygous mice, but not in 
homozygous animals. By contrast, the increase in DA turnover was significantly 
elevated in all genotypes (Fig. 20). In the ventral striatum, an exposure effect was 
established for HVA (F1,46=31.3, p<0.001)(Table 5b). The exposure effect was 
also significant (F1,46=11.1, p<0.01) for DA turnover in the ventral striatum (Fig. 
20), but post hoc analysis did not establish any significant changes between the 
groups (Visnapuu et al., 2013). 
 
 
Table 5. Effect of exposure of Wfs1-deficient mice to the motility boxes compared to mice taken 
from the home-cage on the metabolism of dopamine in the dorsal and ventral striatum.  Mean 
values ± SEM are presented in the table. Data are expressed as pmol/mg of tissue weight 























DA 46.1±3.2 46.6±3.4 52.2±4.8 49.1±2.6 50.5±3.4 46.0±2.8 
DOPAC 6.5±1.0 7.9±0.7 7.6±1.0 9.1±0.8 7.4±0.8 6.8±1.2 
HVA 3.9±0.3 6.3±0.5* 4.9±0.5 7.4±0.5* 4.4±0.3 5.9±0.5 




DA 26.5±3.0 30.5±4.5 33.7±3.9 35.0±4.0 25.8±2.3 29.6±2.7 
DOPAC 5.7±0.9 5.8±0.7 4.9±0.4 7.4±1.1 5.1±0.6 3.9±0.6 
HVA 3.7±0.4 5.8±0.5* 4.1±0.2 6.5±0.7* 3.6±0.2 5.0±0.3 
3-MT 3.6±0.2 3.8±0.2 3.2±0.3 3.9±0.5 2.9±0.2 2.5±0.2 
* – p < 0.05 compared to the respective group of naive mice (Tukey HSD test after significant 
two-way ANOVA). DA – Dopamine; DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – 
Homovanillic acid; 3-MT – 3-Methoxytyramine. There were 5 male and 5 female mice in each 




Figure 20. Effect of exposure to the motility boxes on DA turnover in the dorsal and 
ventral striatum. * – p < 0.05 compared to respective group of mice not exposed to the 
motility boxes (Tukey HSD test after significant two-way ANOVA). HVA – Homo-
vanillic acid; DA – Dopamine. Data are expressed as ratio between the levels of HVA 
(pmol/mg) and DA (pmol/mg) in the respective brain structures. There were 5 male and 
5 female mice in each group (Visnapuu et al., 2013). 
 
 
Effect of amphetamine on locomotor activity and dopamine metabolism in 
the dorsal and ventral striatum 
30 minutes after treatment with amphetamine (5 mg/kg), animals were placed 
into the motility boxes and their locomotor activity was measured. As a result, a 
gene-dose effect on amphetamine-induced hyperlocomotion was established 
(Fig. 21). Altogether, similarly to our previous study (Luuk et al., 2009, Study 
1) amphetamine-induced locomotor stimulation was clearly stronger in wild-
type mice compared to their heterozygous and homozygous littermates. Two-
way ANOVA revealed significant effects of genotype and treatment on all 
measures of motor activity (genotype effects: time in locomotion F2,53=9.78, 
p<0.001, distance travelled F2,53=8.82, p<0.001, number of corner entries 
F2,53=5.57, p<0.01; treatment effects: time in locomotion F1,53=54.0, 
p<0.001, distance travelled F1,53=55.7, p<0.001; number of corner entries 
F1,53=43.4, p<0.001; genotype and treatment interactions: time in locomotion 
F2,53=3.62, p<0.05, distance travelled F2,53=5.94, p<0.01, number of corner 
entries F2,53=4.83, p<0.05). According to post hoc analysis, the elevation of all 
measures of locomotor activity of amphetamine-treated wild-type and 
heterozygous mice was statistically significant compared to the respective 
saline-treated groups (p<0.05, Tukey HSD) (Fig. 21). There was a significant 
difference between amphetamine-treated wild-type and homozygous mice for 
all measures of locomotor activity (p<0.05, Tukey HSD). The difference in 
distance travelled after treatment with amphetamine was also significant when 




Figure 21. Effect of amphetamine (5 mg/kg) on the locomotor activity of Wfs1-
deficient mice. Amphetamine-induced locomotor stimulation was clearly stronger in 
wild-type mice compared to their heterozygous and homozygous littermates. * – p  
< 0.05 compared to the respective group of saline treated mice (Tukey HSD test after 
significant two-way ANOVA); + – p < 0.05 (compared to amphetamine-treated wild-
type mice).There were 5 male and 5 female mice in each group (Visnapuu et al., 2013). 
 
 
In the biochemical studies, treatment with amphetamine caused significant 
changes in DA metabolism in the dorsal and ventral striatum. In the dorsal 
striatum, genotype effect was significant for DA (F2,53=3.50, p<0.05) and for 
its metabolite 3-MT (F2,53=5.99, p<0.01) (Table 6A). Treatment effect was 
significant for DA (F1,53=19.2, p<0.001), DOPAC (F1,53=44.7, p<0.001), 
HVA (F1,53=24.0, p<0.001), 3-MT (F1,53=11.5, p<0.01) (Table 6A) and DA 
turnover (F1,53=68.3, p<0.001) (Fig. 21). Genotype and treatment interaction 
was established for DA (F2,53=3.19, p<0.05) and for DA turnover it was close 
to being significant (F2,53=2.74, p=0.07). Amphetamine was found to increase 
the levels of DA and lower DOPAC and DA turnover in the dorsal striatum of 
wild-type mice when compared to saline-treated wildtype mice (p<0.05, Tukey 
HSD test) (Table 6A, Fig. 22). In heterozygous mice, amphetamine caused a 
significant reduction of levels of DOPAC and HVA, but also increased the level 
of 3- MT. Moreover, DA turnover was also reduced in these mice. We found a 
reduction of DOPAC in response to amphetamine in homozygous mice. Besides 
that, homozygous mice displayed significantly lower levels of DA and 3-MT in 
the dorsal striatum in response to amphetamine compared to their wild-type 
littermates (Visnapuu et al., 2013). 
In the ventral striatum, a genotype effect was established for DOPAC 
(F2,49=8.92, p<0.001) and 3-MT (F2,49=12.5, p<0.001) (Table 6B). Treatment 
effect was significant for DA (F1,49=4.68, p<0.05), DOPAC (F1,49=9.16, 
p<0.01), HVA (F1,49=8.99, p<0.01), 3-MT (F1,49=9.41, p<0.01) and DA 
turnover (F1,49=24.7, p<0.001). The interaction of genotype with treatment was 
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close to statistical significance in the case of DA turnover (F2,49=2.80, p=0.07). 
In wild-type mice, amphetamine induced a significant increase in the level of 
DA and reduced DA turnover (Table 6B, Fig. 22). In heterozygous mice, an 
increase in the level of 3-MT was evident. Also, the levels of DOPAC, HVA 
and the turnover of DA were reduced in heterozygous mice. The level of 3-MT 
in homozygous mice, after treatment with amphetamine, was significantly lower 
compared to heterozygous and wild-type animals. Amphetamine did not induce 
a significant reduction of DA turnover in the ventral striatum of homozygous 
mice. Altogether, the strongest differences between the genotypes were 
established for the elevation of DA levels under the influence of amphetamine 
in the dorsal and ventral striatum. There was a clear gene-dose effect similar to 
that established for amphetamine-induced hyperlocomotion (Fig. 22, Table 6A, 
6B). Moreover, amphetamine was not able to induce a statistically significant 
suppression of DA turnover in the dorsal and ventral striatum of homozygous 
mice (Visnapuu et al., 2013). 
 
 
Table 6. Effect of amphetamine (5 mg/kg) on the metabolism of dopamine in the dorsal 

























DA 46.6±3.4 69.3±6.1*+ 49.1±2.6 63.6±2.9 46.0±2.8 50.7±4.2 
DOPAC 7.9±0.7 4.5±0.5* 9.1±0.8 3.7±0.6* 6.8±1.2 3.0±0.6* 
HVA 6.3±0.5 4.7±0.4 7.4±0.5 4.5±0.7* 5.9±0.5 4.3±0.4 





DA 30.5±4.5 46.0±5.0*+ 35.0±4.0 42.3±4.0 29.6±2.7 31.7±3.3 
DOPAC 5.8±0.7 4.5±0.8 7.4±1.1 4.9±0.9* 3.9±0.6 2.1±0.4 
HVA 5.8±0.5 4.1±0.6 6.5±0.7 4.4±0.4* 5.0±0.3 4.9±0.7 
3-MT 3.8±0.2 4.8±0.7+ 3.9±0.5 5.5±0.5*+ 2.5±0.2 3.0±0.3 
Mean values ± SEM are presented in the table. Data are expressed as pmol/mg of tissue weight.   
* – p < 0.05 compared to the respective group of saline treated mice (Tukey HSD test after 
significant two-way ANOVA); + – p < 0.05 compared to homozygous mice treated with 
amphetamine. DA – Dopamine; DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – 
Homovanillic acid; 3-MT – 3-Methoxytyramine. There were 5 male and 5 female mice in each 




Figure 22. Effect of amphetamine (5 mg/kg) on the turnover of dopamine in the dorsal 
and ventral striatum. * – p < 0.05 compared to respective group of saline treated mice 
(Tukey HSD test after significant two-way ANOVA). HVA – Homovanillic acid; DA – 
Dopamine. Data are expressed as ratio between the levels of HVA (pmol/mg) and DA 
(pmol/mg) in the respective brain structures. There were 5 male and 5 female mice in 
each group (Visnapuu et al., 2013). 
 
Effect of apomorphine on motor activity and dopamine levels in the dorsal 
and ventral striatum 
In the case of treatment with apomorphine, a two-way ANOVA established that 
only treatment effect was significant for all measures of locomotor activity 
(time spent in locomotion F1,54=15.3, p<0.001, distance travelled F1,54=11.3, 
p<0.01 and the number of corner entries F1,54=16.7, p<0.001). Administration 
of apomorphine (3 mg/kg) tended to increase the locomotor activity in wild-
type mice, but this effect was not statistically significant (Fig. 23). Apo-
morphine-treated heterozygous mice displayed significantly longer distance 
travelled and a greater number of corner entries compared to saline-treated 
heterozygous mice. Homozygous Wfs1-deficient mice had a significant increase 
in time spent in locomotion compared to the respective saline-treated group 
(p<0.05, Tukey HSD) (Visnapuu et al., 2013). 
 
 
Figure 23. Apomorphine (3 mg/kg) induced changes in locomotor activity of Wfs1-
deficient mice * – p < 0.05 compared to the respective group of saline treated mice 
(Tukey HSD test after significant two-way ANOVA). There were 5 male and 5 female 
mice in each group (Visnapuu et al., 2013). 
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In the dorsal striatum, treatment effect of apomorphine was significant for 
DOPAC (F1,52=43.8, p<0.001), HVA (F1,52=117.2, p<0.001) (Table 7A) and 
DA turnover (F1,52=95.1, p<0.001) (Fig. 24). Genotype and treatment 
interaction was significant for HVA (F2,52=3.26, p<0.05). Apomorphine 
significantly reduced the levels of HVA, DOPAC, and DA turnover in the 
dorsal striatum of all genotypes (Visnapuu et al., 2013). 
In the ventral striatum, treatment effect of apomorphine was significant for 
DOPAC (F1,50=8.97, p<0.01), HVA (F1,50=57.9, p<0.001), 3-MT (F1,50= 
5.38, p<0.05) (Table 7B), and DA turnover (F1,50=58.1, p<0.001) (Fig. 24). 
Apomorphine caused a significant reduction of HVA and DA turnover in the 
ventral striatum of all genotypes. In heterozygous mice, the level of DOPAC 
was also reduced in the ventral striatum in response to apomorphine (Visnapuu 
et al., 2013). 
 
 
Figure 24. Effect of apomorphine (3 mg/kg) on the turnover of dopamine in the dorsal 
and ventral striatum. * – p < 0.05 compared to the respective group of saline treated 
mice (Tukey HSD test after significant two-way ANOVA). HVA – Homovanillic acid; 
DA – Dopamine. Data are expressed as ratio between the levels of HVA (pmol/mg) and 
DA (pmol/mg) in the respective brain structures. There were 5 male and 5 female mice 
in each group (Visnapuu et al., 2013). 
 
 
Tables 7. Effect of exposure to apomorphine (3 mg/kg) on the metabolism of dopamine 



























DA 46.6±3.4 49.9±3.3 49.1±2.6 43.3±3.1 46.0±2.8 52.7±3.4 
DOPAC 7.9±0.7 4.3±0.5* 9.1±0.8 3.3±0.8* 6.8±1.2 3.4±0.4* 
HVA 6.3±0.5 3.3±0.5* 7.4±0.5 2.4±0.3* 5.9±0.5 2.5±0.2* 





DA 30.5±4.5 28.0±5.3 35.0±4.0 35.1±3.8 29.6±2.7 39.3±6.5 
DOPAC 5.8±0.7 4.8±1.0 7.4±1.1 3.9±0.4* 3.9±0.6 3.1±0.4 
HVA 5.8±0.5 2.9±0.5* 6.5±0.7 3.1±0.4* 5.0±0.3 2.8±0.4* 
3-MT 3.8±0.2 3.0±0.5 3.9±0.5 3.1±0.5 2.5±0.2 1.9±0.2 
Mean values ± SEM are presented in the table.  Data are expressed as pmol/mg of tissue weight.  
* – p < 0.05 compared to the respective group of saline treated mice (Tukey HSD test after 
significant two-way ANOVA). DA – Dopamine; DOPAC – 3,4-Dihydroxyphenylacetic acid; 
HVA – Homovanillic acid; 3-MT – 3-Methoxytyramine. There were 5 male and 5 female mice in 
each group (Visnapuu et al., 2013). 
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Amphetamine-induced motor sensitization in Wfs1-deficient mice 
During the course of repeated treatments with amphetamine (2.5 mg/kg) its 
motor stimulating effect became steadily stronger in male wild-type animals. 
Repeated measures three-way ANOVA established the following main and 
interaction effects: time in locomotion [F2,76=10.2, p<0.001 (genotype); 
F5,76=4.1, p<0.01 (day); F5,76=13.9, p<0.001 (day x treatment)], distance 
travelled [F2,76=6.33, p<0.01 (genotype); F1,76=6.92, p<0.05, (treatment); 
F5,76=9.74, p=0.09 (day x treatment)] and number of corner entries 
[F2,76=3.29, p<0.05 (genotype); F1,76=7.2, p<0.01 (treatment), F5,76=5.28, 
p<0.01 (day x treatment)]. Post hoc analysis (Tukey HSD test) revealed that in 
wild-type mice the effect of amphetamine on the 6th day was significantly 
increased compared to the administration of saline on the 6th day and to the 
treatment with amphetamine on the 1st day (Fig. 25). In heterozygous mice, 
there was some increase in the action of amphetamine, but this change was not 
statistically significant. Repeated treatments with amphetamine even tended to 
reduce the locomotor activity in homozygous mice (Fig. 25). Therefore, in the 
amphetamine sensitization study, a gene-dose effect was established in Wfs1-
deficient mice as in the case of acute treatment with the higher dose of 
amphetamine (5 mg/kg) (Visnapuu et al., 2013). 
 
 
Figure 25. Sensitization of Wfs1-deficient mice to amphetamine-induced motor stimu-
lation. * – p < 0.05 compared to amphetamine-treated wild-type mice on the first day;  
¤ – p < 0.05 compared to saline-treated wild-type mice on the sixth day; # – p < 0.05 
compared to amphetamine-treated homozygous mice on the 6th day. (Tukey HSD after 
significant three way repeated measures ANOVA.) The number of animals in each 
group was 13-14 (Visnapuu et al., 2013). 
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Expression of Dat (midbrain) and Drd2 (dorsal and ventral striatum) 
mRNA in Wfs1-deficient mice 
The expression level of Dat mRNA in the midbrain was significantly affected in 
male and female mice (F2,20=3.95, p<0.05 and F2,47=4.82, p<0.05, respec-
tively). Post hoc analysis established a significantly lower level of Dat ex-
pression in homozygous animals of both sexes (Fig. 26A and 25B) (Visnapuu et 




Figure 26. Expression of Dat gene in the mesencephalon of Wfs1-deficient mice: A. 
Dat mRNA in the mesencephalon of female mice; B. Dat mRNA in the mesencephalon 
of male mice * – p < 0.05 compared to wild-type animals (Tukey HSD after significant 
one-way ANOVA). The number of animals in each group was 16-17 in case of females 
and 7-8 in case of males (Visnapuu et al., 2013). 
 
 
The expression level of Drd2 gene in the ventral striatum of both male and 
female mice was not affected by the disruption of the Wfs1 gene (Fig. 26B and 
26D). However, we found a significantly reduced Drd2 receptor level in the 
dorsal striatum of male homozygous mice compared to wild-type animals 
(F2,15=6.32, p<0.05) (Fig. 26A), while in the female mice it was unaffected 




Figure 27. Expression of Drd2 gene in Wfs1-deficient mice. Relative Drd2 mRNA 
levels in the dorsal (A) and ventral striatum (B) of male mice and relative Drd2 levels in 
the dorsal (C) and ventral striatum (D) in female mice. * – p < 0.05 compared to wild-
type animals (Tukey HSD after significant one-way ANOVA). The number of animals 





Expression of Dat protein in the dorsal and ventral striatum of Wfs1 
deficient mice 
In the dorsal striatum Dat protein level tended to be lower both in the male and 
female homozygous mice. However, this difference was not statistically 
significant. (Fig. 28 A, C) (Visnapuu et al., 2013). 
 
 
Figure 28. Expression of Dat protein in the dorsal and ventral striatum of Wfs1-
deficient mice. Relative Dat protein levels in the dorsal (A) and ventral (B) striatum of 
male mice and relative Dat protein levels in the dorsal (C) and ventral (D) striatum of 
female mice. No significant difference (p> 0.05, Mann-Whitney U) was found in Dat 
protein levels between wild-type mice and Wfs1 homozygous mice. The number of 
animals was 6-7 in each group. Abbreviation: Protein ladder (L), str – striatum (Visna-
puu et al., 2013). 
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7. DISCUSSION 
7.1.  Wfs1-deficient mice display impaired behavioural 
adaptation in stressful environment 
In Study 1 we provided a behavioural profile of female Wfs1-deficient F2 gene-
ration mice with mixed background [(129S6/SvEvTac × C57BL/6) × (129S6/ 
SvEvTac × C57BL/6)]. To make the Wfs1 gene nonfunctional, exon 8, the 
principal coding exon, was disrupted which resulted in premature termination of 
the Wfs1 protein. Absence of Wfs1 C-terminal immunostaining in Wfs1-defi-
cient mice has been demonstrated previously (Luuk et al., 2008). Nonfunctio-
nality of the Wfs1 gene was confirmed by intolerance to glucose challenge, a 
finding consistently reported in Wfs1-deficient mice by other groups employing 
different strategies of Wfs1 disruption (Ishihara et al., 2004; Riggs et al., 2005). 
For general phenotyping of Wfs1-deficient mice, we used only young adult 
female mice as they displayed milder metabolic disturbances than male mice 
and older mice (Luuk et al., 2009). 
The behaviour of Wfs1-deficient mice did not differ from that of wild-type 
littermates in terms of motor performance in the rota-rod and forced swimming 
tests, but several measures of general motor activity such as time spent in 
locomotion, distance travelled and the number of rearings in the motility box, 
and swimming speed in the Morris water maze test were consistently di-
minished in Wfs1-deficient mice. In most cases, however, these effects 
remained at tendency level. Also, no obvious disruptions in sensory functioning 
were observed in the behavioural tests used. Wfs1-deficient mice appeared 
normal in heat-induced pain perception, were able to differentiate between 
brightly and dimly lit environments, developed intact responses to electric foot-
shocks and a 10 kHz conditioned auditory stimulus, and were able to navigate 
by means of visual contextual cues in Morris water maze. Wfs1-deficient mice 
displayed no gross learning deficits as evidenced by intact learned responses to 
conditioned fear-eliciting stimuli, as well as the existence of spatial memory in 
the Morris water maze test (both wild-type and knockout mice showed 
preference for the target quadrant after both initial and reversal training). 
However, during reversal training Wfs1-deficient mice covered significantly 
longer distances before finding the platform than their wild-type littermates. 
This subtle impairment in reversal learning may be indicative of dysfunction in 
the hippocampal and/or prefrontal circuits as in humans and monkeys, 
impairments in reversal learning have been associated with orbitofrontal cortex 
dysfunction (Jentsch et al., 2002; Waltz and Gold, 2007). In mice, hippocampal 
CA1 and CA3 regions have been implicated specifically in reversal learning 
(Havekes et al., 2006). Notably, both the prefrontal cortex and hippocampal 
CA1 region are enriched in Wfs1 protein and mRNA (Lein et al., 2007; Luuk et 
al., 2008). The metabolic profile of Wfs1-deficient female mice revealed lower 
body weight at 4 months of age by latest, and intolerance to intraperitoneal 
65 
administration of glucose. However, we observed no differences in baseline 
concentrations of blood glucose in non-fasted animals (Luuk et al., 2009). 
It is notable that in most cases altered behavioural responses were es-
tablished when Wfs1-deficient mice were exposed to novel environments or 
stressful manipulations. In the hyponeophagia test, Wfs1-deficient mice 
displayed increased behavioural inhibition in a novel environment as their 
latency to start eating was significantly longer than in wild-type littermates. 
Also, the locomotor activity was significantly lower in Wfs1-deficient mice 
compared to wild-type mice only in the more aversive bright environment as 
opposed to dim environment. Similarly, short-term social isolation of Wfs1-
deficient mice induced significant anxiety-like behaviour in the light-dark box 
exploration test when compared to non-isolated mice. In contrast, social 
isolation had no major impact on the behaviour of wild-type mice in the same 
test. The relatively higher sensitivity of Wfs1-deficient mice to environmental 
stressors was further supported by increased analgesic response after electric 
foot-shocks of intermediate intensity and a nearly three-fold higher plasma 
corticosterone concentration after handling and injection stress when compared 
to wild-type littermates (Luuk et al., 2009). 
Corticosterone measurements revealed no differences in baseline concentra-
tions between wild-type and Wfs1-deficient mice. A higher level of anxiety in 
Wfs1-deficient mice was suggested by the administration of a moderate dose of 
diazepam (1 mg/kg) which had a robust anxiolytic-like effect on plus-maze 
behaviour in Wfs1-deficient mice but not in the wild-type mice. It is also of 
interest that some (as an average approximately 20–30%) of Wfs1-deficient 
mice produced spontaneous audible vocalizations which increased in loudness 
under stressful conditions and were suppressed by the administration of dia-
zepam. Neuroanatomical evidence indicating an enrichment of Wfs1 expression 
in the central extended amygdala and paraventricular hypothalamic nucleus 
(Becker et al., 2008; Luuk et al., 2008) also supports the conclusion that the 
behaviour of Wfs1-deficient mice can best be described by increased anxiety 
response. Rather than being a single anatomical entity, the extended amygdala 
concept stands for a network of basal ganglionic nuclei with similar con-
nectivity and neurochemical properties forming a functional-anatomical 
macrostructure involved in the etiology of such neuropsychiatric disorders as 
anxiety and depression (Alheid et al., 1988; Heimer, 2003). The paraventricular 
hypothalamic nucleus, on the other hand, is involved in the endocrine regulation 
of stress response by controlling the activity of the hypothalamic–pituitary–
adrenocortical (HPA) axis, secretion of neurohypophysial peptides such as 
vasopressin and oxytocin, and by regulating autonomic centres in brainstem and 
spinal cord (Herman et al., 2008; Luuk et al., 2009). 
The psychomotor stimulant effects of amphetamine and apomorphine, the 
drugs that exert their effects through the dopamine system, were different in 
Wfs1-deficient mice compared to wild-type mice. At intermediate and high 
doses the stimulatory effect of amphetamine was significantly weaker in Wfs1-
deficient mice, which is probably indicative of lower presynaptic release 
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potential for dopamine in the mesolimbic and nigrostriatal pathway. On the 
other hand, postsynaptic dopamine receptor agonist apomorphine induced 
significantly higher locomotor activation in Wfs1-deficient mice reflecting most 
likely postsynaptic upregulation of dopamine receptors in the ventral and dorsal 
striatum. As opposed to the present results, reduction in the effect of apo-
morphine has been demonstrated by Rowland et al. (Rowland et al., 1985) in 
hypoinsulinaemic mice displaying otherwise a similar behavioural profile in 
terms of lower basal locomotor activity (Owens et al., 2005; Sevak et al., 2007) 
and resistance to the motor stimulatory properties of amphetamine and other 
related psychomotor stimulants (Marshall et al., 1978; Merali et al., 1988; 
Rowland et al., 1985). Therefore, the behavioural phenotype of Wfs1-deficient 
mice is probably not reducible to just indirect effects of metabolic disturbances 
resulting from impaired stimulus-secretion coupling of insulin in the pancreatic 
beta-cells. In mice, Wfs1 protein is expressed at high levels in the ventral 
striatum (nucleus accumbens and olfactory tubercle) and, to a lesser degree, in 
the caudal part of dorsal striatum while being undetectable in the more 
voluminous rostral part and dopaminergic neurons residing in ventral tegmental 
area and compact part of substantia nigra (Luuk et al., 2008). Hence, the 
nucleus accumbens is the most obvious candidate for producing disturbances in 
dopaminergic transmission in Wfs1-deficient mice. Although mostly known as 
the brain structure mediating the reinforcing actions of addictive drugs (Koob 
and Moal 2001) the nucleus accumbens has been additionally implicated in the 
regulation of anxiety and stress response (Barrot et al., 2002; Barrot et al., 
2005). In addition to high Wfs1 expression in neuronal perikarya in the core and 
shell regions of nucleus accumbens, there is a prominent Wfs1-rich projection 
from the nucleus accumbens to the reticular part of substantia nigra and less 
dense projections of unknown origin to the compact part of substantia nigra and 
ventral tegmental area (Luuk et al., 2008). Hypothetically, reduced activation of 
Wfs1-positive neurons in the nucleus accumbens leading to increased inhibitory 
tone on motor regions targeted by inhibitory efferents from the reticular part of 
substantia nigra could account for behavioural inhibition apparent in Wfs1-
deficient mice. Such a situation is plausible as Wfs1-deficiency has been shown 
to reduce stimulus-secretion coupling in pancreatic beta-cells (Ishihara et al., 
2004; Takei et al., 2006; Luuk et al., 2009). 
The behavioural phenotype of male Wfs1-deficient mice has been described 
by another research group who generated their mutant mice by means of a 
genetic ablation of the second exon of the Wfs1 gene, resulting in full knock-
out mice (Kato et al., 2008). In these mice, behavioural alterations are less 
apparent than in the present study. Homozygous Wfs1-deficient mice and their 
wild-type littermates differed significantly in terms of increased escape 
latencies during the conditioning phase in the passive avoidance test and in the 
first block of trials on day 3 of the active avoidance test, in terms of increased 
freezing during conditioning phase in the fear conditioning test, and in terms of 
increased latency to find the platform during training phase of the Morris water 
maze. These results support the idea that the Wfs1-deficient mice generated by 
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Kato et al., 2008 have subtle impairments in behavioural activation in 
demanding situations. Generally, however, the behavioural differences in these 
mice are quite modest compared to our Wfs1-deficient mouse line. Also, Kato 
et al., 2008 reported no alterations in body weight or other phenotypic para-
meters. The markedly increased severity of phenotypic alterations in Wfs1 
deficient mice in the present study could be due to several reasons. First, our 
Wfs1 targeting strategy spared amino acids 1–359 of Wfs1 protein whereas in 
the other knockout no N-terminal immunoreactivity of Wfs1 was retained 
(Ishihara et al., 2004). Thus, in our mice, the functionality of Wfs1 protein is 
disrupted while its N-terminal cytoplasmic region is free to interact with its 
molecular partners possibly prohibiting the activation of compensatory 
pathways. Furthermore, Ishihara et al., 2004 have demonstrated that the 
diabetogenic effect of Wfs1-deficiency is considerably weaker in C57BL/6 
background when compared to F2 intercross bearing a more or less equal and 
random mix of 129S6/SvEvTac and C57BL/6 genetic material (Wolfer et al., 
2002). The results of our behavioural experiments indicate that the dependency 
of phenotypic severity on genetic background extends also to the central 
nervous system. This is not unexpected as the differential impact of 129S6-
derived and C57BL/6 inbred genetic backgrounds on anxiety-like behaviour is 
well known (Abramov et al., 2008; Holmes et al., 2003; Hovatta et al., 2005). 
Also, differences in experimental design may have contributed to the 
differences between the two Wfs1-deficient mouse lines. We have seen 
previously that long-term social isolation induces an anxiety-like state in female 
mice, whereas increased aggressiveness and exploratory drive are observed in 
males (Abramov et al., 2004). Kato et al., 2008 studied male mice housed 
individually for several days, whereas in our experiments group-housed female 
mice were used. Lastly, the order of experiments can also have an impact on the 
observed phenotype because a number of behavioural tests are sensitive to 
previous experience and/or handling. For example, Kato et al. (2008) never 
performed plus-maze as the first test, however, it known that the plus-maze 
exposure is extremely sensitive to previous experience (Voikar et al., 2007) and 
therefore we always perform it as the very first test of a behavioural battery and 
always with naive mice (Luuk et al., 2009). 
 
 
7.2. Relation between increased anxiety and reduced 
expression of alpha1 and alpha2 subunits of GABA(A) 
receptors in Wfs1-deficient mice  
The results of the behavioural battery described above indicate that the genetic 
invalidation of Wfs1 induces an impaired adaptation response in mice in a novel 
and stressful environment in terms of increased anxiety in ethological models. 
Pre-treatment with diazepam (1 mg/kg), an anxiolytic drug acting via GABAA 
receptors, antagonized increased anxiety and stress-induced vocalizations in 
Wfs1-deficient mice (Luuk et al., 2009). As GABA-ergic system plays a 
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significant role in the regulation of anxiety, and the α1 subunit of GABAA 
receptor is responsible for the sedative effects of diazepam and α2 subunit plays 
a role in its stimulating action (Olsen et a., 2009; Wafford et al., 2004), we 
analyzed the expression of Gabra1 and Gabra2 in the forebrain structures, 
showing high expression of Wfs1 protein (frontal cortex, temporal lobe, 
hippocampus and mesolimbic area) (Luuk et at., 2008) of wild-type and Wfs1-
deficient mice. Besides that the expression levels of Gad1 and Gad2 genes, the 
enzymes responsible for synthesis of GABA from glutamate, were measured in 
the same forebrain structures (Raud et al., 2009). 
The genetic invalidation of the Wfs1 gene increased not only anxiety in mice 
(Luuk et al., 2009), but also affected the expression level of the Gabra1 and 
Gabra2 genes, playing a role in the pharmacological action of diazepam. 
Namely, Wfs1-deficient mice displayed reduced expression of these genes in 
the temporal lobe and frontal cortex. Both these structures have been shown to 
play an eminent role in the regulation of negative emotions, especially anxiety 
(Finn et al., 2003). The down-regulation of two dominating subunits of GABAA 
receptors (Henschel et al., 2008) probably reflects reduced GABA-ergic neuro-
transmission in these particular brain regions. Reduced activity of the GABA-
ergic system may also explain the increased sensitivity of Wfs1-deficient mice 
to the anxiolytic action of diazepam (Luuk et al., 2009). On the other hand, the 
lack of changes in the expression of the Gad1 and Gad2 genes demonstrates that 
the invalidation of the Wfs1 gene does not have a major impact on the synthesis 
of GABA in the brain. Lyons et al., 2001 have shown that the long-term 
exposure of brain neurons to GABA results in down-regulation of GABAA 
receptor number and uncoupling of GABA and benzodiazepine binding sites. 
They have revealed that the down-regulation of GABAA receptors occurs due to 
GABA-induced elevation of intracellular Ca2+ levels. Therefore, in the light of 
finding that the Wfs1 protein modulates Ca2+ levels in the intracellular space 
(Takei et al., 2006), one could speculate that the elevated release of GABA due 
to heightened sensitivity to stress of Wfs1-deficient mice may be responsible for 
the down-regulation of GABAA receptor subunits. It is noteworthy that a similar 
down-regulation of the Gabra1 and Gabra2 genes in the temporal lobe and 
frontal cortex occurred in wild-type mice in response to exposure to the 
elevated plus-maze. This finding further underlines a possible role of stress in 
the down-regulation of GABAA receptor subunits established in Wfs1-deficient 
mice. Therefore, one can state that the present study is in favor of a relation 
between increased anxiety and reduced expression of subunits of GABAA 
receptors in the frontal cortex and temporal lobe in Wfs1-deficient mice (Raud 




7.3. Evidence for impaired function of dopaminergic 
system in Wfs1-deficient mice 
As in the above described study 1 the locomotor activity of saline-treated male 
homozygous Wfs1-deficient mice tended to be lower compared to their 
heterozygous and wild-type littermates. Moreover, 5 mg/kg of amphetamine, an 
indirect DA agonist, caused a gene-dose dependent increase of locomotor 
activity. Specifically, amphetamine-induced hyperlocomotion was the strongest 
among wild-type mice and weakest in homozygous animals. A diminished 
effect in Wfs1-deficient mice was also detected for sub-threshold dose (2.5 
mg/kg) of amphetamine – repeated treatments with this dose of amphetamine 
caused significant motor sensitization in wild-type mice, but not in their 
heterozygous and homozygous littermates. By contrast, apomorphine (3 mg/kg), 
a direct DA agonist, caused a significant motor stimulation in heterozygous and 
homozygous Wfs1-deficient mice, but not in wild-type mice. The nature of 
these behavioral and pharmacological alterations was further explored by 
biochemical measurements of DA and its metabolites in the dorsal (involving 
the caudate putamen) and ventral (involving the nucleus accumbens and 
olfactory tubercle) striatum.  
Exposure of saline-treated mice to the motility boxes revealed a significantly 
stronger increase in the tissue level of homovanillic acid (HVA), a major 
metabolite of DA, both in the dorsal and ventral striatum of wild-type and 
heterozygous mice compared to their homozygous littermates. This change 
probably reflects an increased utilization of DA in wild-type and heterozygous 
animals under the influence of exposure. The established finding is consistent 
with the above described locomotor activity experiment where the activity of 
homozygous mice tended to be lower compared to the other genotypes. 
Treatment with amphetamine (5 mg/kg) significantly increased tissue levels of 
DA in the dorsal and ventral striatum of wild-type mice, but not in their 
homozygous littermates. This finding probably reflects an impaired release of 
DA in Wfs1- deficient mice. This statement coincides with a recent study 
showing that depolarization-induced release of DA is severely blunted in Wfs1-
deficient mice (Matto et al., 2011). Besides that, the influence of amphetamine 
on DA turnover was significantly reduced in the dorsal and ventral striatum of 
homozygous animals compared to other genotypes. It is known that the 
administration of DA agonists reduces turnover of DA as a homeostatic 
mechanism (Bannon et al., 1980; Garcia et al., 2005). In the case of the 
disruptionof the Wfs1 gene, this biochemical action of amphetamine is 
diminished, because amphetamine is unable to augment tissue levels of DA in 
the dorsal and ventral striatum. However, treatment with apomorphine caused a 
similar reduction of DA utilization across all genotypes. Therefore, one could 
suggest that the disruption of Wfs1 gene does not affect the regulation of DA 
metabolism via DA receptors. To a certain extent, this hypothesis is supported 
by the finding that the expression of Drd2 gene (gene for DA D2 receptor) was 
not affected in the ventral striatum of both male and female Wfs1-deficient 
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animals. Although in the dorsal striatum of male Wfs1- deficient mice the 
expression of Drd2 gene was reduced, in female homozygous mice it remained 
unchanged (Visnapuu et al., 2013). 
In order to further clarify the reasons for reduced efficacy of amphetamine in 
Wfs1-deficient mice we measured gene and protein expression levels of DA 
transporter, a major target in the action of amphetamine (Sulzer et al., 2005). 
First, the gene expression measurements revealed marked differences between 
genotypes. In both sexes, the expression level of Dat gene was significantly 
reduced in the midbrain of homozygous mice compared to wild-type animals. 
We aimed to substantiate gene expression findings with protein analyses. 
Although there were no significant statistical differences between genotypes, 
the level of Dat protein remained lower in the dorsal striatum of male and 
female homozygous mice compared to wild-type animals. This tendency was 
not seen in the ventral striatum. There might be two factors contributing to not 
having overlap between gene and protein analyses. First, the obtained protein 
expression data are too variable and it is likely that bigger group sizes would 
allow to establish an effect in the dorsal striatum. Secondly, it has been shown 
that mRNA and protein abundances are not always unidirectional or 
overlapping (Muller et al., 2011; Pra – llner et al., 2001; Visnapuu et al., 2013). 
In conclusion, it is likely that Wfs1 gene deficiency impairs the release of 
DA and therefore compromises the function of DA-ergic system. Although the 
precise mechanism remains to be elucidated, a possible reason for this 
manifestation could be the altered Ca2+ signaling observed in Wfs1-deficient 
mice. For instance, Ishihara et al.  (2004) have demonstrated a reduced Ca2+-
dependent stimulus-secretion coupling for insulin in Wfs1-deficient mice. 
Taking into account the above cited study by Matto et al. (2011), showing that 
depolarization-induced DA release is blunted in Wfs1-deficient mice, one could 
suggest a similar alteration of Ca2+ signaling for DA transmission in the brain. 
However, this hypothesis needs to be verified by further studies. On the other 
hand, amphetamine-induced release of DA depends on the activity of DA 
transporter. Results of the present study introduce the possibility that the 
activity of DA transporter is reduced in Wfs1-deficient mice. Several lines of 
evidence coming from recent literature show that insulin signaling, via 
phosphatidylinositol 3-kinase (PI3K) and Akt, effectively modulates DA 
transporter activity (Garcia et al., 2005; Wei et al., 2007, Williams et al., 2007). 
Indeed, the inhibition of insulin-mediated PI3K signaling reduces the cell 
surface expression of Dat protein, and DA uptake is reduced as a result 
(Williams et al., 2007). Therefore, pharmacologically induced insulin 
deficiency (caused by steptozotocin) apparently down-regulates the level of DA 
transporter (Williams et al., 2007), suppresses amphetamine-induced DA 
release (Owens et al., 2012; Williams et al., 2007) and hyperlocomotion in 
rodents (Owens et al., 2005). However, there is a substantial difference between 
streptozotocin and Wfs1-deficiency induced changes in the DA-ergic system. 
Namely, Owens et al. (2012) have found that repeated treatment with amphe-
tamine in rats reverses the reduced sensitivity to amphetamine induced by 
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streptozotocin, whereas in the present study the administration of sub-threshold 
dose of amphetamine (2.5 mg/kg) has been unable to affect the reduced 
sensitivity of Wfs1-deficient mice toward amphetamine. Accordingly, one 
could claim that altered Ca2+ signaling is a possible reason for the observed 
alterations in the function of DA-ergic system in Wfs1-deficient mice and the 
reduced expression of DA transporter is likely a compensatory change to the 
inhibited DA release (Visnapuu et al., 2013). 
 
 
7.4. Relevance of Wfs1 deficient mice as an model of WS 
The studies performed so far demonstrate that Wfs1 deficient mice can be taken 
as a relevant model of WS (Ishihara et al., 2004; Riggs et al., 2005). It is known 
that diabetes occurring in WS patients begins earlier and is more severe in male 
persons (Noormets et al., 2011). The similar severity of metabolic disturbances 
is true concerning male Wfs1 deficient mice. The elevation of blood glucose 
during glucose tolerance test is much more serious and it lasted longer in male 
homozygous mice compared to their female littermates (Noormets et al., 2011). 
Therefore, the male Wfs1 deficient mice have more pronounced growth 
retardation compared to female ones. This growth retardation is accompanied 
by the activation of growth hormone pathways and substantial elevation of IGF-
1 levels in the plasma (Kõks et al., 2009). On the other hand, the development 
of diabetic symptoms in the case of Wfs1 deficiency depends on the genetic 
background. C57/Bl6 background is apparently protective against the develop-
ment of symptoms (Ishihara et al., 2004). The dependence of outcomed of 
WFS1 gene mutations from the genetic background may be a possible reason 
why WS is very pleiomorphic disease, i.e. different patients display different 
symptoms. Therefore, one could suggest that the metabolic effects of Wfs 
deficiency should be studied either in 129Sv background or in F2-hybrids 
having the randomly mixed background from C57/Bl6 and 129Sv parents. In 
the case of behavioural phenotyping the mixed background is more preferrable, 
because the behavioural abilities of 129Sv mice are in some cases limited. We 
have found that the stress-related vocalizations are much louder and more 
frequent in F2 hybrids compared to 129Sv background. Altogether, based on 
these data it looks like that Wfs1 deficient mice to certain extent resemble to 
that of seen in the case of human disease – WS.  
The roles of serotonin and noradrenaline in the mechanism and treatment of 
depression have been widely discussed and proven (Delgado et al., 1990; Moret 
et al., 2011; Neumeister et al., 2004). However, it has become apparent that 
dopamine in the ventral and dorsal striatum, involved in the neural circuits of 
motivations and reward, plays a distinct role in the neurobiology of depression 
(Salamone et al., 2012). Taking into account a possible role of dopamine in 
depression, one could suggest that the impaired function of dopamine system, 
established in Wfs1-deficient mice, may be extended to the patients suffering 
from mutations in wolframin1 gene to explain their depressive symptoms. 
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8. CONCLUDING REMARKS AND  
FUTURE PROSPECTS 
The present study demonstrates that Wfs1 gene deficiency impairs the adap-
tation of mice in the novel and stressful environment Table 8).  The subsequent 
studies revealed that the altered adaptation is probably related to the impaired 
function of GABA- and dopaminergic systems. There are clear indications for 
the reduced activity of GABAergic system in Wfs1 deficient mice. The 
expression of dominating (α1 and α2) subunits of GABAA receptors is reduced 
in the temporal lobe and frontal cortex of genetically modified mice. This is 
accompanied by the elevated anxiety and increased anxiolytic action of 
diazepam, an agonist of GABAA receptors (Table 8). The function of dopami-
nergic system is also impaired. Wfs1 gene deficiency impairs the release of DA 
and therefore compromises the function of DA-ergic system. Although the 
precise mechanism remains to be elucidated, a possible reason for this mani-




Table 8. The major findings of study 
Aim of the study Findings and statements 
1. Behavioural phenotyping of 
Wfs1 deficient mice 
Wfs1 deficient mice display the impaired 
adaptation in novel and stressful environment 
2. Characterization of GABA 
system in Wfs1 deficient mice 
Increased anxiety established in Wfs1 deficinet 
mice is related to the impaired function of 
GABA system in the temporal lobe and frontal 
cortex 
3. Characterization of dopamine 
system in Wfs1 deficient mice 
Altered adaptation established in Wfs1 
deficient mice is related to the compromised  
function of dopamine system due to the 
impaired release of neurotransmitter 
4. Validity of Wfs1 deficient mice 
as a model of WS 
Deficient regulation of glucose metabolism, 
occuring in Wfs1 deficient mice resembles to 
that seen in the patients suffering from WS. 
Therefore, Wfs1 deficient mice can be taken as 
a valid model of WS and compromised function 
of GABA and dopamine system, established in 




It is known that insulin mediates the release of adrenaline and noradrenaline 
from adrenergic terminals in neurons, inhibits adrenaline and noradrenaline 
reuptake in the neural synapse, modifies the kinetics of catecholamines, 
stimulates serotonin reuptake and regulates transport of DAT to the cell 
membrane (Duarte et al., 2012). Insulin also controls the expression of NMDA 
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receptors by increasing the influx of Ca2+ ions and thereby strengthening the 
synaptic communication between neurons (Duarte et al., 2012). Therefore, 
insulin modulates the long-term activation of neurons and learning on a mole-
cular level. Furthermore, insulin controls the extracellular concentration of 
glutamate, aspartate, taurine, GABA and GABAA receptors (Duarte et al., 
2012). Moreover, the brain regions rich in insulin (brain cortex, olfactory bulb, 
hippocampus, hypothalamus and amygdala) overlap in a great extent with the 
brain structures where the expression level of Wfs1 is the highest (Luuk et al., 
2008; Duarte et al., 2012). Therefore, the Wfs1 gene may have a vital role in the 
production and release of insulin in the central nervous system and this could be 
the reason why WS patients develop such severe neurological impairments. 
Taken together, the relevance of insulin for development of behavioural 
phenotype established in Wfs1 deficient mice should be the target of following 
studies with these genetically modified animals. Moreover, the depressive 
symptoms are frequent in patients suffering from WS as well as in the hetero-
zygous carriers of WFS1 gene mutations (Swift et al., 1998).  Thus, the beha-
vioural effects of various antidepressant drugs (imipramine, paroxetine) should 
be evaluated in Wfs1 deficient mice.  Simultaneously, the alterations in the 
activity of serotonin- and noradrenergic neurotransmission should be studied in 





1. The mice with a deleted exon 8 in the Wfs1 gene do not have any noticable 
sensory deficiencies. They have a normal pain sensitivity and they can 
successfully navigate in the Morris water maze. They have a normal learning 
curve in the active avoidance test. Also, their locomotor activity does not differ 
from that of their wild-type littermates in the motility box, Morris water maze 
and forced swimming test. However, Wfs1-deficient mice reacted with in-
creased anxiety in stress-inducing environments as evidenced by longer 
latencies to eat in the hyponeophagia test, anxiety-like behaviour in the light-
dark test in response to short-term social isolation and decreased exploratory 
activity in the open field test in intense lighting conditions. Also, their level of 
corticosterone after a stress-inducing intraperitoneal saline injection is three 
times higher than in their wild-type littermates and they display increased 
sensitivity to diazepam, GABAA receptor agonist, in the elevated plus maze test. 
Diazepam also eliminated audible vocalizations characteristic to Wfs1 deficient 
mice in a stressful situation. In addition, these mice have alterations in the 
dopaminergic system. They have markedly lower sensitivity to the locomotor 
stimulating effects of amphetamine, an undirect agonist of dopamine, and they 
display hypersensitivity to the locomotor stimulating effect of apomorphine, a 
direct agonist of dopamine, compared to their wild-type littermates. Altogether, 
the initial behavioural phenotyping of Wfs1 deficient mice reflected their 
impaired adaptation in the novel and stressful environment. 
2. The mice with a deleted exon 8 in the Wfs1 gene have a lower expression 
level of the Gabra1 and Gabra2 genes in the temporal lobe and frontal cortex, in 
the brain structures playing a role in the regulation of negative emotions. These 
genes code the alpha1 and alpha2 subunits of the GABAA receptor, being the 
important mediators of the pharmacological effects of diazepam. This is 
probably a reason for the increased anxiolytic effect of diazepam in Wfs1 
deficient mice. The similar change in expression of Gabra1 and Gabra2 gene in 
wild-type mice was established after their challenge to the elevated plus-maze, 
demonstrating a relation between anxiety and these subunits of GABAA 
receptors. The decrease in the expression of the Gabra1 and Gabra2 genes 
indicates an impairment in GABA-ergic neurotransmission in Wfs1-deficient 
mice. There is no differences in the expression levels of glutamate decarbo-
xylase (Gad1 and Gad2) genes, indicating that Wfs1-deficiency does not induce 
profound changes in the GABA synthesis in mice. 
3. Amphetamine (5 mg/kg), significantly increased the locomotor activity of 
wild-type and heterozygous mice, but had almost no effect on the activity level 
of homozygous mice with the deleted 8th exon in Wfs1 gene. In addition, 
repeated administration of low dose (2.5 mg/kg) of amphetamine failed to 
induce a motor sensitization in homozygous mice. Amphetamine (5 mg/kg) 
administration increased significantly the level of dopamine in the ventral and 
dorsal striatum in wild-type mice, but not in homozygous mutants. Also, 
amphetamine administration significantly decreased the dopamine turnover in 
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the ventral and dorsal striatum in wild-type and heterozygous mice, but not in 
homozygous mutants. Motor stimulation induced by apomorphine (3 mg/kg) 
was somewhat stronger in mutant mice compared to wild-type animals. 
However, treatment with apomorphine induced a similar decrease in dopamine 
turnover in all genotypes, which indicates that the deficiency of Wfs1 gene does 
not influence dopamine metabolism via dopamine receptors. This statement is 
also confirmed by results of the gene expression experiment where the gene 
expression of Drd2 receptors between genotypes was not different in the ventral 
striatum. However, both female and male Wfs1-deficient mice had a lower level 
of the dopamine transporter gene in the midbrain. This finding together with the 
blunted behavioral and biochemical effects of amphetamine is indicative for the 
impaired function of dopaminergic system in Wfs1 deficient mice. 
4. Based on studies of glucose metabolism it is obvious that the mice with 
the deleted 8th exon of Wfs1 gene are the valid models of WS and related 
disorders. Therefore, the established disturbances in Wfs deficient mice 
occurring in the function of GABA- and dopaminergic system can be extended 
to understand the neuropsychiatric symptoms in WS patients. 
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1 . SUMMARY IN ESTONIAN 
Wolframi sündroomi mudel hiirtel: käitumuslik, biokeemiline ja 
psühhofarmakoloogiline iseloomustamine 
Wolframi sündroom (WS, OMIM 222300) on haruldane autosomaalne retses-
siivne neurodegeneratiivne häire, mida iseloomustavad varajases lapseeas algav 
suhkurtõbi, progresseeruv nägemisnärvi atroofia, magediabeet ja kurtus (Dome-
nech et al., 2006). WS iseloomustasid esmakordselt Saksa arstid Wolfram ja 
Wagener 1938.a (Wolfram and Wagner 1938). Wolframi sünroomi põhjustavad 
mutatsioonid Wolframiin 1 (WFS1) geenis (Strom et al., 1998; Inoue et al., 
1998). Antud sündroomile on iseloomulikud terve rida neuroloogilisi ja psüh-
hiaatrilisi sümptomeid, mille hulka kuuluvad raske depressioon, psühhoos, üle-
määrane impulsiivsus ja agressiivsus (Barrett et al., 1995; Swift et al., 1991; 
Swift et al., 1990). Wfs1 on seotud hirmu ja ärevusega hiirtel ja rottidel (Kesner 
et al., 2007; Koks et al., 2002) ja tema polümorfismid on tõenäoliselt seotud 
suurenenud meeleoluhäirete riskiga (Koido et al., 2005).  
WfS1 geen asub inimese 16 kromosoomis lookuses 4p16.1 (Strom et al., 
1998; Inoue et al., 1998). Paljud uuringud on seda kromosoomi piirkonda seos-
tanud bipolaarse häirega (Ewald et al., 1998, 2002; Detera-Wadleigh et al., 
1999), bipolaarse häire psühhootilise vormi (Als et al., 2004; Cheng et al., 
2006) ning suitsidaalse käitumisega (Cheng et al., 2006). Nende uuringute 
alusel võib oletada, et WFS1 geeni mutatsioonid omavad teatud rolli bipolaar-
sete häirete ja teiste depressiivsete seisundite patofüsioloogias (Kato et al., 
2008).  
Inimestel, kes kannavad erinevaid WFS1 geeni mutatsioone, kuid ei oma 
WS ilminguid, on 26 korda suurem risk sattuda psühhiaatriahaiglasse, enamasti 
depressiooni tõttu (Swift et al., 1998). On näidatud WFS1 geeni mutatsioonide 
esinemist mitmete neuropsühhiaatriliste häirete puhul (skisofreenia, bipolaarne 
häire, depressioon, suitsidaalne käitumine) (Ohtsuki et al., 2000; Martorell et 
al., 2003; Torres et al., 2001; Crawford et al., 2002; Evans et al., 2000), kuid 
oluline on siin rõhutada, et ükski neist patsientidest ei omanud WS iseloomu-
likke ilminguid. Vaatamata sellele, et WFS1 geeni mutatsioonid ei ole tõenäo-
liselt eriti sagedaseks vaimuhaiguste tekke põhjuseks, on oluline ikkagi selgi-
tada võimalikke neurobioloogilisi mehhanisme, mille kaudu WFS1 puudulikkus 
viib WS patisentidel ning heterosügootstel mutatsiooni kandjatel vaimsete 
häirete välja kujunemiseni (Kato et al., 2008).  
Käesoleval ajal ei ole veel päris selge, mis moodi WFS1 geeni puudulikkus 
põhjustab neuropsühhiaatriliste kõrvalekallete ilmnemist. Kuid võttes arvesse 
WS puhul esinevad psühhiaatrilised sümptomid (Barrett et al., 1995; Swift et 
al., 1991; Swift et al., 1990), ning ka Wfs1 geeni ja valgu lokalisatsiooni ajus 
(Luuk et al., 2008), võib arvata, et ühetedeks põhjustajateks võivad olla 
kõrvalekalded GABA- ja dopamiinergilise süsteemi talitluses. Depressiooni ja 
ärevushäirete vahel esinev silmapaistev komorbiidsus viitab nende haiguste 
etioloogilisele sarnasusele (Murphy et al., 2004; Gamez et al., 2007). Pidurdus-
mediaatori γ-aminovõihappe (GABA) kontsentratsiooni vähenemine ajus ja 
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virgatsaine toimes põhiliste GABAA retseptorite funktsiooni muutus või 
ekspressiooni vähenemine on seotud nii depressiooni kui ka ärevushäirete 
väljakujunemisega (Luscher et al., 2011). Samuti on leitud, et dopamiinergilise 
süsteemia alafunktsioon, esmajoones prefrontaalses koores, on seotud depres-
siooni ja skisofreenia negatiivsete sümptomitega (apaatia, huvi kadumine, anhe-
doonia jne.) (Davis et al., 1991). Vastupidiselt, dopamiinergilise süsteemi üle-
funktsiooni, iseäranis ventraalses ja dorsaalses striatumis, on seostatud skiso-
freenia positiivsete sümptomidega: hallutsinatsioonid, luulumõtted, psühhomo-
toorne rahutus ja kontrollimatu käitumine (Davis et al., 1991). Nimetatud 
kõrvalekalded GABA- ja dopamiinergilise süsteemi talitluses on vägagi sarnan-
sed nendele häiretele, mida on kirjeldatud WS põdevatel patsientidel (Swift et 
al., 1998). 
Käesoleva doktoritöö keskseks eesmärgiks oli WS hiire mudeli loomine. 
Selleks valmistati mutantne hiireliin kustutades Wfs1 geenist 8nda eksoni ja 
asendades selle beeta galaktosidaasi ekspresiooni kassetiga (NLS-LacZ). 
Kaheksas ekson valiti, sest meie eelduseks oli C-terminaali „funktsiooni kaoga“ 
Wfs1 puudulikkusega hiire loomine, kuna WS patsientidel enamik mutatsioone 
asub just selles eksonis. Selline lähenemisviis aitas luua WS sarnase seisundi, et 
uurida sündroomi poolt esilekutsutud patoloogilisi muutusi.  
Katseloomade iseloomustamiseks kasutati käitumuslikke (ärevus, motoorne 
koordinatsioon, motoorne aktiivsus, õppimine ja mälu, valutundlikkus, katse-
loomade reaktsioon stressile jne.), biokeemilisi (dopamiini ja tema peamisete 
metaboliitide sisalduse määramine katseloomade ajus, geeni ja valgu ekspres-
siooni uurimine ajustruktuurides, glükoosi tolerantsuse test, kortikosterooni 
taseme määramine vastusena stressile) ja psühhofarmakoloogilisi (GABAA 
retseptorite agonist diasepaam, dopamiini agonistid amfetamiin ja apomorfiin) 
uurimismeetodeid. Katsete tulemuste usaldusväärtust kontrolliti statistiliste 
meetoditega, kasutades selleks Statistica for Windows 10 arvutiprogrammi.   
Uuringute käigus jõuti järgmiste tulemusteni. Wfs1 geeni kaheksanda eksoni 
puudulikkusega hiirtel ei olnud nähtavaid sensoorseid häireid. Neil oli nor-
maalne valutundlikkus ja nad suutsid orienteeruda väliste märkide järgi Morrise 
vesipuuris. Nende õppimine aktiivse vältimise testis ei erinenud metsik-tüüpi 
pesakonna kaaslaste omast. Samuti ei erinenud nende käitumine motoorika 
testis, Morrise vesipuuris ja sundujumise testis. Wfs1 puudulikkusega hiired 
reageerisid suurenenud ärevusega stressi esilekutsuvates keskkondades. Nii oli 
pikenenud nende söömise alustamise latents hüponeofaagia testis, vähenenud 
oli nende uudistamisaktiivsus heleda-tumeda puuri testis peale lühiajalist isolat-
siooni ja nad olid vähem aktiivsed avarvälja testis suurema keskkonna valgus-
tatuse korral. Samuti suurenes neil tunduvalt enam, võrreldes metsik-tüüpi 
hiirtega, korikosterooni tase ringlevas veres peale füsioloogilise lahuse akuutset 
süstimist. Wfs1 puudulikkusega hiirtel oli suurenenud tundlikkus GABAA 
retseptorite agonisti diasepaami ärevusvastase toime suhtes. Diasepaam kõrval-
das ka Wfs1 puudulikksuega hiirtele iseloomulikud häälitsemised stresso-
geenses situatsioonis. Lisaks kõigele muule esinesid nendel hiirtel kõrvale-
kalded dopamiinergilise süsteemi funktsioonis. Nende tundlikkus amfetamiini, 
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kaudse dopamiini agonisti, motoorikat stimuleeriva toime suhtes oli vähenenud, 
kuid nende tundlikkus oli suurenenud apomorfiini (dopamiini otsese agonisti) 
toime suhtes võrreldes metsik-tüüpi pesakonnakaaslastega. Kokkuvõttes, 
esialgne käitumuslik fenotüpeerimine peegeldab Wfs1 puudulikkusega hiirte 
häirunud võimet kohaneda uudses ja stressogeenses keskkonnas.  
Wfs1 geeni kaheksanda eksoni puudulikusega hiirtel oli vähenenud Gabra1 
ja Gabra2 geenide eskpressioon oimusagaras ja otsmikukoores ehk ajustruk-
tuurides, mis on seotud negatiivsete emotsioonide regulatsiooniga. Need geenid 
kodeerivad  GABAA retseptori alfa1 ja alfa2 alaühiku valke, mis on olulised 
diasepaami farmakoloogiliste toimete vahendajad. Gabra 1 ja Gabra 2 geenide 
ekspressiooni langus on ilmselt seotud Wfs1 puudulikkusega hiirtel esineva 
ülitundlikkusega diasepaami ärevusvastase toime suhtes. Sarnane Gabra1 ja 
Gabra2 geeniekspressiooni langus esines metsik-tüüpi hiirtel peale  nende 
eksponeerimist pluss puuris (ärevuse mudel), mis viitab, et on olemas seos 
GABAA retseptorite alatüüpide ekspressiooni languse ja ärevuse vahel. Kokku-
võttes, Gabra1 and Gabra2 geenide ekspressiooni langus viitab GABA-ergilise 
närviülekande häirumisele Wfs1 puudulikkusega hiirte. Samas ei ole erinevusi 
glutamaat dekarboksülaasi (Gad1 ja Gad2) geenide ekspressioonis, mille alusel 
võib väita, et GABA biosüntees ei ole Wfs1 geeni puudulikkuse mõjul häiritud.  
Amfetamiin (5 mg/kg) suurendas oluliselt liikumisaktiivsust metsik-tüüpi ja 
heterosügootsetel hiirtel, kuid mitte homosügootsetel mutantsetel hiirtel. Lisaks 
sellele, amfetamiini madalate annuste (2,5 mg/kg) korduv manustamine ei kut-
sunud esile motoorset sensitisatsiooni homosügootsetel hiirtel, võrreldes metsik 
tüüpi pesakonna kaaslastega. Amfetamiini (5 mg/kg) manustamine suurendas 
märkimisväärselt dopamiini taset metsik-tüüpi hiirte dorsaalses ja ventraalses 
striatumis, aga mitte homosügootsetel mutantidel. Samuti vähendas amfetamiini 
manustamine dopamiini ringkäiku metsik-tüüpi ja heterosügootsete hiirte dor-
saalses ja ventraalses striatumis, kuid see ei leidnud aset homosügootsetel 
mutantidel. Apomorfiinist (3 mg/kg) tingitud motoorika stimulatsioon oli mõne-
võrra tugevam mutantsetel hiirtel võrreldes metsik-tüüpi hiirtega. Kuid apo-
morfiin põhjustas kõikidel fenotüüpidel ühesugust dopamiini ringkäiku vähe-
nemist, mille alusel võib väita, et Wfs1 geeni puudulikkus ei mõjusta dopamiini 
metabolismi dopamiini retseptorite vahendusel. Seda väidet kinnitavad ka geeni 
ekspressiooni tulemused, kus dopamiini retseptori (Drd2) ekspressioon oli 
ühesugune kõikide genotüüpide ventraalses striatumis. Siiski oli nii emastel kui 
ka isastel Wfs1 puudulikusega hiirtel vähenenud dopamiini transporteri geeni 
ekspressioon keskajus. See leid koos amfetamiini käitumuslike ja biokeemiliste 
toimete vähenemisega viitab dopamiinergilise süsteemi funktsiooni olulisele 
häirumisele Wfs1 puudulikkusega hiirtel.  
Põhinedes glükoosi metabolismi uuringute tulemustele ja nende sarnasusele 
WS on selge, et Wfs1 geeni kaheksanda eksoni puudulikkusega hiir on valiid-
seks mudeliks WS südnroomile ja ka teistele WFS1 geenimutatsioonidest tingi-
tud häiretele. Sellepärast võib käesolevas uuringus leitud muutusi dopamiini- ja 
GABA-ergilise süsteemi aktiivsuses Wfs1 puudulikkusega hiirtel laiendada WS 
patsientidele, et mõista nendel esinevaid neuropsühhiaatrilisi sümptomeid.  
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